Gastroenterology Insights — Clinical Updates, Guides & Resources — Page 5

5 min readAug 3, 202666reads

IBD Biologic Sequencing After Anti-TNF and Vedolizumab Failure: Choosing the Third-Line Agent

A 31-year-old woman with ileocolonic Crohn's disease has lost response to adalimumab after eighteen months, switched to vedolizumab, and now presents at week 30 with a CRP of 42, a calprotectin over 800, and a repeat colonoscopy showing unhealed ulceration. Two mechanisms are gone. The next choice is no longer obvious, and it carries more weight than either of the first two. The core clinical problem Sequencing after a single biologic failure is well-trodden ground — the data on anti-TNF-to-vedolizumab or anti-TNF-to-ustekinumab switches is deep, and most gastroenterologists move through it reflexively. Dual failure is different. Once anti-TNF and vedolizumab have both failed, the remaining evidence base is thinner, drawn mostly from post-hoc trial subgroups and real-world cohorts rather than trials designed around this population. IBD biologic sequencing after anti-TNF and vedolizumab failure has to account for how mechanism of failure — immunogenic loss of response versus primary non-response versus mechanistic exhaustion — changes the odds for whatever comes next, and clinicians who treat this decision the same way they treated the first switch tend to underestimate how much efficacy has already eroded. What the data actually shows about efficacy decay Across pivotal trials for ustekinumab, vedolizumab, and risankizumab, remission rates fall in a fairly consistent stepwise pattern as prior biologic exposure accumulates — patients with zero or one prior failure respond meaningfully better than those with two or more. The upadacitinib U-ENDURE program is the clearest illustration of this in a dual-refractory population specifically: efficacy outcomes were stratified not just by number of prior failures but by which classes had failed (anti-TNF, ustekinumab, vedolizumab/natalizumab), and patients with prior failure of two or more mechanisms still derived clinical benefit from upadacitinib, though at lower absolute rates than biologic-naive patients. That is the central, practice-changing finding for this scenario: a JAK inhibitor doesn't reset the deck, but it does not appear to lose efficacy proportionally to the number of prior mechanisms exhausted, which distinguishes it from what's typically seen when cycling between antibody classes with overlapping resistance patterns. Sequencing decisions get harder still in fistulizing phenotypes — see our post on ustekinumab for fistulising perianal Crohn's disease and what the GETAID trial adds for how mechanism choice changes when perianal disease is in the picture. Per the ACG Clinical Guideline for Crohn's disease, the decision after dual biologic failure should also reconsider whether the original diagnosis, phenotype, and disease location were fully characterized — stricturing or penetrating disease that looks like drug failure is sometimes a surgical problem wearing a pharmacologic mask. Case in point A 44-year-old man with Crohn's ileitis failed infliximab due to antibody formation at month nine, then failed vedolizumab with adequate trough levels and no antibodies after seven months of therapy — a mechanistic non-response rather than an immunogenic one. Repeat imaging confirmed active inflammation without stricture. Given confirmed mechanistic (not pharmacokinetic) failure of both an anti-TNF and an anti-integrin, the team moved to upadacitinib rather than cycling to ustekinumab, reasoning that a genuinely different pathway — JAK-STAT inhibition rather than another surface-receptor-targeted antibody — offered better odds than a third antibody-class agent given how the first two had failed. He achieved clinical response by week 8 and endoscopic improvement at week 26. Choosing between ustekinumab, risankizumab, and JAK inhibition as the third agent The comparison usually comes down to two questions: how much of the original response was pharmacokinetic versus mechanistic, and how much the safety profile matters for this particular patient. Ustekinumab or risankizumab (IL-12/23 or IL-23 blockade): A reasonable next mechanism if trough levels on the prior anti-TNF or vedolizumab were adequate but response still failed — genuine mechanistic failure of the first two pathways doesn't predict failure of a third that hasn't been tried. IL-23-selective agents like risankizumab now have head-to-head data against ustekinumab in this setting and a favorable long-term safety record. Upadacitinib or other JAK inhibitors: Worth prioritizing when the patient has failed multiple antibody-based mechanisms, when extraintestinal manifestations (peripheral arthritis, in particular) are prominent, or when oral dosing matters for adherence. The trade-off is a boxed warning profile that requires a real conversation about cardiovascular and thromboembolic risk, especially in patients over 65 or with existing risk factors. If genuinely useful to the patient in front of you, framing it as pharmacokinetic failure → try a mechanism-appropriate re-challenge or dose optimization, versus mechanistic failure → change class entirely, keeps the decision tractable instead of defaulting to "whatever hasn't been tried yet." A frequently overlooked point The instinct after two failures is to treat the third agent selection as the most important decision in the case, but the more consequential error is skipping therapeutic drug monitoring before making that call. A patient labeled as a vedolizumab failure with subtherapeutic troughs and no antibodies hasn't failed the mechanism — they've failed the dose. It's also worth ruling out a genuinely different driver before cycling to a fourth mechanism: a subset of refractory patients carry anti-IL-10 neutralizing autoantibodies rather than conventional treatment-resistant IBD — a mechanistically distinct, HLA-linked subtype that downstream cytokine blockade won't touch, and one worth testing for before assuming you've simply run out of biologics. Bottom line for clinical practice Confirm mechanistic failure with trough levels and antibody testing before concluding a drug — rather than a dose — has failed. After confirmed dual mechanistic failure, JAK inhibition (upadacitinib) retains meaningful efficacy and doesn't appear to decay proportionally with prior biologic count, per U-ENDURE subgroup data. Reserve a third antibody-class agent (ustekinumab or risankizumab) for cases where the prior two failures were pharmacokinetic, immunogenic, or otherwise mechanism-specific rather than a true ceiling on antibody-based therapy. Re-image or re-scope before assuming pharmacologic failure — stricturing disease masquerading as drug failure is a surgical referral, not a fourth biologic. Discuss cardiovascular and thromboembolic risk explicitly before starting a JAK inhibitor in this population; the discussion belongs in the chart, not just the consent form. Cases like this rarely resolve from a single guideline table — they need the trough levels, the imaging, and the phenotype pulled together in one place before the next agent gets chosen. Walk GastroAGI through a case like this and it will return a reasoned, guideline-anchored response in seconds.

GastroAGI TeamRead more

15 min readJul 31, 202696reads

REFINED-ASUC Criteria: A Modern Approach to Diagnosing Acute Severe Ulcerative Colitis

Patients rarely read the textbook before arriving in hospital. A patient with ulcerative colitis may present with frequent bloody stools, tachycardia, anaemia, low albumin, nocturnal bowel movements, and a rising inflammatory burden—but may already have been taking oral corticosteroids for several days. Another may be receiving an advanced therapy that partially suppresses fever or C-reactive protein without adequately controlling the colitis. Neither patient necessarily presents in the classical manner described by criteria developed more than 70 years ago. This is the problem addressed by the article: “New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC.” Published online in Clinical Gastroenterology and Hepatology on July 22, 2026, the paper reports the work of the Refined Evaluation Framework and INvEstigations for Diagnostics in ASUC, known more conveniently as the REFINED-ASUC Working Group. Its DOI is 10.1016/j.cgh.2026.07.011. The study does not compare drugs, rescue therapies, or surgical strategies. It is not a randomized trial, a prospective patient cohort, or a treatment guideline. It is a modified Delphi consensus designed to answer a deceptively difficult question: How should acute severe ulcerative colitis be diagnosed when modern therapy has already altered the patient’s presentation? That question matters because diagnosing acute severe ulcerative colitis, or ASUC, is not simply an exercise in classification. The diagnosis may trigger hospital admission, infection testing, endoscopic assessment, radiologic evaluation, close physiological monitoring, intravenous treatment, early rescue-therapy planning, and surgical consultation. In severe colitis, diagnostic delay is rarely improved by optimism. Why the traditional ASUC definition now feels incomplete The diagnosis of ASUC has traditionally relied on the 1955 Truelove and Witts criteria. These criteria have endured because they are clinically practical and historically important. They helped generations of clinicians recognize a dangerous form of ulcerative colitis that required urgent inpatient management. However, the therapeutic world in which those criteria were developed was very different from modern inflammatory bowel disease practice. Today, a patient may arrive in hospital while already receiving: Oral corticosteroids Biologic therapy Small-molecule treatment Combination treatment Previous rescue therapy Treat-to-target monitoring Treatment may alter the clinical phenotype. Corticosteroids may reduce fever or suppress the C-reactive protein response. Advanced therapies may partially improve bowel frequency without adequately controlling bleeding. A patient may appear less systemically inflamed on paper while still having dangerous mucosal disease. This creates a clinical dilemma. Should a patient be considered less severely ill because one laboratory marker has been partially suppressed by treatment? Or should the threshold for concern change because the patient is already receiving therapy that ought to have improved the disease? REFINED-ASUC addresses this mismatch by incorporating treatment exposure directly into diagnostic reasoning. That is perhaps its most important conceptual contribution. Treatment history is no longer background information. It becomes part of the diagnostic framework. A familiar scenario in modern IBD practice Consider a patient with established ulcerative colitis who has been taking high-dose oral corticosteroids for several days. The patient reports six or seven bowel movements daily, visible blood in roughly one-third of them, nocturnal symptoms, progressive fatigue, and reduced oral intake. The CRP is elevated, but not dramatically so. Under a rigid interpretation of older criteria, the patient may appear not to satisfy every expected marker of systemic severity. Yet something is clearly wrong. The patient is already receiving treatment that should have reduced inflammation. The persistence of bleeding, frequent bowel movements, nocturnal symptoms, and systemic decline may therefore be more concerning—not less. This is where experienced clinical judgment often begins to whisper before the criteria begin to shout. REFINED-ASUC attempts to turn some of that modern clinical reasoning into a more structured diagnostic framework. How the REFINED-ASUC consensus was developed The study used a four-round Delphi process followed by a consensus meeting. The participating experts were gastroenterologists from: Europe North America The Asia-Pacific region Together, they formed the REFINED-ASUC Working Group. Consensus was defined as: At least 70% agreement or disagreement for Likert-scale questions At least 70% homogeneity for single-choice or multiple-choice responses This methodology is appropriate when clinical practice has evolved more quickly than the available validation evidence. A Delphi process allows experts to review statements repeatedly, reconsider their positions, and move toward a defined level of agreement. It is particularly useful when developing diagnostic definitions, research frameworks, or consensus terminology. However, its limitations must be understood. The participants were expert gastroenterologists—not hospitalized patients. There was no patient-level intervention. There was no treatment comparator. The outcomes were consensus statements and proposed diagnostic criteria, not colectomy rates, mortality, steroid response, or long-term remission. A Delphi consensus tells us what knowledgeable experts agreed should be considered. It does not prove that the resulting criteria predict clinical outcomes. Expert agreement is valuable. Nature, unfortunately, is not obliged to agree with the experts until the criteria are tested prospectively. The proposed REFINED-ASUC diagnostic framework For patients already receiving advanced therapy or corticosteroids, the REFINED-ASUC group reached consensus on a structure involving: Three major criteria plus at least two minor criteria. The three major criteria The proposed major criteria are: C-reactive protein at least two times the upper limit of normal At least six bowel movements per 24 hours Visible blood in at least 50% of bowel movements over 24 hours These criteria combine inflammatory burden, stool frequency, and bleeding severity. This matters because no single component adequately captures the clinical syndrome. Frequent bowel movements alone may occur for several reasons. CRP may be affected by treatment or individual biological variation. Bleeding alone does not define the full systemic severity of the illness. Together, however, they describe a patient with active, clinically significant colitis despite ongoing therapy. The minor criteria The proposed minor criteria are: Low albumin Increased heart rate Nocturnal bowel movements Low haemoglobin Increased body temperature Elevated leukocyte count These minor criteria broaden the framework beyond stool counting. They capture nutritional deterioration, inflammatory stress, blood loss, systemic response, and disruption of normal daily physiology. Anyone who has looked after patients with severe ulcerative colitis knows that nocturnal bowel movements carry a particular significance. A bowel that repeatedly wakes the patient during the night is not respecting office hours, and severe inflammation rarely does. Why the major-plus-minor structure is clinically meaningful The proposed framework recognizes that ASUC is not simply “diarrhoea with a high CRP.” It is a severe inflammatory syndrome with multiple dimensions: Stool frequency Visible bleeding Systemic inflammation Anaemia Nutritional compromise Tachycardia Fever Leukocytosis Nocturnal disease activity A major-plus-minor structure may help clinicians identify patients who are seriously unwell even when no single variable appears dramatic in isolation. For example, imagine a patient receiving advanced therapy who has: Six bowel movements daily Visible blood in more than half CRP more than twice the upper limit of normal Low albumin Tachycardia Nocturnal bowel movements The overall pattern is far more informative than any one value. Clinical severity often lives in the combination. The laboratory system may display each abnormality in a separate row. The clinician’s task is to recognize that the abnormalities belong to the same patient. Why visible bleeding remains central One of the three major criteria is visible blood in at least 50% of bowel movements during 24 hours. This is clinically understandable. Visible bleeding supports the presence of ongoing active mucosal inflammation and helps distinguish severe colitis from other causes of frequent bowel movements, including functional symptoms, medication effects, or non-inflammatory diarrhoea. In a severe ulcerative colitis flare, bleeding is not merely an inconvenient symptom. It represents continuing mucosal injury. However, the threshold must be interpreted carefully. The source supports this percentage as a consensus-derived diagnostic component. It does not prove that 49% represents low risk while 50% represents high risk. Biology is rarely impressed by a one-percentage-point administrative boundary. Nor does the consensus establish that the visible bleeding threshold independently predicts colectomy, treatment failure, or mortality. It is a proposed diagnostic marker requiring prospective validation. The threshold should support judgment, not replace it. High-dose corticosteroids require different thinking One of the most intellectually interesting aspects of REFINED-ASUC is its separate consideration of patients already receiving high-dose corticosteroids. For this subgroup, the panel supported lower thresholds: CRP at least one times the upper limit of normal Visible blood in at least 33% of bowel movements over 24 hours Why lower the thresholds? Because high-dose corticosteroids may partly suppress the inflammatory expression of disease. A patient already receiving substantial corticosteroid treatment may not demonstrate the same degree of CRP elevation or bleeding burden as an untreated patient, even when the underlying disease remains severe. Waiting for more dramatic abnormalities may therefore delay recognition. Consider a patient who has already received several days of high-dose corticosteroids but continues to experience frequent stools, one-third visibly bloody, nocturnal symptoms, anaemia, and tachycardia. The persistence of this disease activity despite therapy should increase concern. The patient has not merely arrived with severe symptoms. The patient has failed to improve adequately despite treatment intended to suppress them. REFINED-ASUC therefore makes an important diagnostic adjustment: The meaning of a clinical finding depends partly on what treatment preceded it. This is sensible medicine. A temperature of 37.8°C means one thing in an untreated patient and may mean something different in a patient receiving medication that suppresses inflammation. The same principle applies to CRP and bleeding burden. What about patients who have not received treatment? The panel agreed that similar diagnostic principles might apply to untreated patients. However, formal consensus was not achieved for that group. This is an important boundary. It would be tempting to describe REFINED-ASUC as a universal replacement for existing ASUC criteria. The source does not support that claim. The strongest consensus applies to patients already receiving advanced therapy or corticosteroids, including a separate approach for patients on high-dose corticosteroids. For untreated patients, the experts saw potential relevance but did not reach the required consensus threshold. Clinicians should therefore present REFINED-ASUC as a modern diagnostic proposal with particular relevance to treated patients—not as a fully established definition for every acute severe ulcerative colitis presentation. Endoscopy still matters The REFINED-ASUC panel agreed that endoscopy should confirm the diagnosis and help exclude cytomegalovirus infection. This is an important reminder that clinical and laboratory criteria do not replace direct assessment of the disease process. Severe colitis may coexist with or be complicated by infection. CMV infection can alter management and may be particularly relevant in patients exposed to immunosuppressive therapy. The criteria may help identify suspected ASUC. Endoscopy helps evaluate the mucosa and assess for competing or contributing pathology. For fellows, the teaching point is straightforward: Do not allow a scoring system to become a substitute for looking at the disease when it is clinically appropriate to do so. A checklist can organize thought. It cannot perform the endoscopy. Radiology and the exclusion of toxic megacolon The panel also agreed that radiologic investigations should support exclusion of toxic megacolon. This is essential because severe colitis is not only an inflammatory problem. It can become a structural and systemic emergency. A patient with abdominal distension, systemic toxicity, tenderness, or concerning clinical deterioration requires assessment beyond stool frequency and CRP. No proposed diagnostic framework should create false reassurance when a major complication is developing. REFINED-ASUC therefore remains part of a broader safety pathway that includes: Clinical assessment Laboratory evaluation Endoscopic confirmation CMV exclusion Radiologic assessment Monitoring for complications The diagnosis of ASUC is a synthesis, not a single laboratory result. How clinicians may use REFINED-ASUC in practice The most reasonable clinical use of REFINED-ASUC is as a structured framework for evaluating contemporary patients whose presentation may have been modified by treatment. When assessing possible ASUC, clinicians may now pay closer attention to documenting: Current and recent corticosteroid exposure Advanced therapy exposure Bowel movement frequency over 24 hours Proportion of bowel movements containing visible blood Nocturnal bowel movements CRP relative to the laboratory upper limit of normal Albumin Haemoglobin Heart rate Body temperature Leukocyte count This may improve communication between emergency clinicians, gastroenterologists, IBD nurses, surgeons, and trainees. “Severe flare” can mean different things to different people. A structured record of bowel frequency, bleeding percentage, treatment exposure, and systemic markers provides a more precise clinical language. It may also help identify patients whose disease is more concerning than the CRP alone suggests. A practical admission scenario Imagine two patients presenting with ulcerative colitis symptoms. Patient A Seven bowel movements daily Visible blood in most stools CRP more than twice the upper limit of normal Low albumin Tachycardia Nocturnal symptoms Currently receiving advanced therapy Patient B Six bowel movements daily Visible blood in one-third CRP just above the upper limit of normal Anaemia Nocturnal symptoms Already taking high-dose corticosteroids The first patient fits the proposed major-plus-minor framework relatively clearly. The second may appear less inflammatory if the CRP is considered without context. However, the lower thresholds proposed for high-dose corticosteroid exposure may appropriately raise concern. This is precisely the type of patient for whom the REFINED-ASUC framework may be useful. It encourages clinicians to ask not only: “How abnormal are the findings?” but also: “How abnormal are these findings given the treatment the patient is already receiving?” That is a more sophisticated clinical question. What REFINED-ASUC does not tell us The source does not prove that applying the proposed criteria will: Reduce colectomy Improve survival Shorten hospital stay Predict corticosteroid failure Identify the ideal rescue therapy Prevent complications Improve long-term remission Reduce readmissions The consensus has not yet been prospectively validated against these outcomes. It is also not a treatment guideline. The study does not compare: Intravenous corticosteroids Infliximab Ciclosporin JAK inhibitors Other rescue strategies Surgical timing Colectomy approaches Its focus is diagnosis. Clinicians should also avoid using the criteria to dismiss serious disease when a patient narrowly fails to meet a numerical threshold. A patient does not become safe because one bowel movement contained insufficient blood to satisfy a percentage calculation. Clinical criteria guide recognition. They do not relieve the clinician of responsibility for the patient in front of them. Strengths of the REFINED-ASUC consensus The greatest strength of the consensus is that it directly addresses modern treatment reality. Many patients presenting with severe ulcerative colitis are no longer treatment-naïve. They may already be receiving therapies that alter symptoms and inflammatory markers. REFINED-ASUC recognizes this explicitly. A second strength is the international composition of the expert group, with gastroenterologists from Europe, North America, and the Asia-Pacific region. A third strength is the structured four-round Delphi process and the use of predefined consensus thresholds. A fourth strength is the breadth of the proposed framework. It does not rely on stool frequency alone but includes bleeding, inflammatory markers, nutritional status, haematologic changes, vital signs, nocturnal symptoms, endoscopy, infection assessment, and radiology. The framework therefore reflects how experienced clinicians actually assess severe colitis: by integrating multiple signals. Important limitations The principal limitation is the evidence type. A modified Delphi process provides expert consensus, not diagnostic validation. The proposed criteria have not yet demonstrated: Sensitivity Specificity Predictive value Reproducibility Prognostic accuracy Impact on clinical outcomes The thresholds also require testing across different laboratories, healthcare systems, patient populations, treatment backgrounds, and disease severities. Using CRP relative to the upper limit of normal may improve portability between laboratories, but that does not guarantee equal performance in all settings. The absence of formal consensus for untreated patients is another important limitation. It prevents the framework from being presented as universal. Finally, some clinical variables—such as the exact proportion of bowel movements containing visible blood—may be difficult to measure reliably in routine care. Patients do not always arrive with a perfectly completed 24-hour spreadsheet, and few would consider that a reasonable expectation during an acute severe flare. Implementation will therefore require practical documentation systems. What future research needs to establish The next step is prospective validation. Future studies should test whether the REFINED-ASUC criteria identify patients who experience: Failure of corticosteroid therapy Need for rescue treatment Colectomy Readmission Complications Prolonged hospitalization Diagnostic reclassification after infection testing Researchers should also examine how the criteria perform across different advanced therapies and corticosteroid doses. Patients receiving treatment should not automatically be considered one homogeneous group. Different therapies may alter clinical and laboratory expression in different ways. Implementation studies will also be necessary. Can clinicians reliably record the proportion of bloody bowel movements? Can nocturnal symptoms be documented consistently? Can electronic admission templates improve data capture? Can the criteria be applied similarly by IBD specialists, general gastroenterologists, emergency physicians, and trainees? A diagnostic framework is only useful when clinicians can apply it accurately at the bedside. Clinical Takeaway The REFINED-ASUC criteria address a genuine problem in modern inflammatory bowel disease care: diagnosing acute severe ulcerative colitis in patients whose clinical presentation may already have been modified by corticosteroids or advanced therapy. For treated patients, the consensus proposes a framework based on three major criteria plus at least two minor criteria. The major criteria are: CRP at least twice the upper limit of normal At least six bowel movements per 24 hours Visible blood in at least 50% of bowel movements The minor criteria include: Low albumin Increased heart rate Nocturnal bowel movements Low haemoglobin Increased temperature Elevated leukocyte count For patients receiving high-dose corticosteroids, lower thresholds were proposed for CRP and visible bleeding. The framework also reinforces the role of endoscopy in confirming disease and excluding CMV infection, together with radiologic assessment for toxic megacolon. The most balanced interpretation is that REFINED-ASUC provides a thoughtful, contemporary diagnostic proposal—not a validated outcome-prediction tool and not a treatment guideline. For clinicians, its greatest value may be intellectual as much as numerical: Disease severity should be interpreted in the context of the treatment the patient has already received. After 25 years in gastroenterology, that principle feels less like a new rule and more like good clinical sense finally being given a formal structure. Five Key Clinical Takeaways REFINED-ASUC is a modified Delphi consensus, not a randomized trial, patient cohort, or treatment guideline. It addresses a modern diagnostic gap by incorporating corticosteroid and advanced therapy exposure into ASUC assessment. For treated patients, the proposed framework uses three major criteria plus at least two minor criteria. Patients receiving high-dose corticosteroids are considered separately, with lower proposed CRP and visible bleeding thresholds. Prospective validation is required before REFINED-ASUC can be considered an established predictor of treatment failure, colectomy, or other clinical outcomes. Source Reference Raine T, Peyrin-Biroulet L, Begun J, Biedermann L, Blumenstein I, Cheifetz AS, Colombel JF, Dulai PS, Gecse KB, Jairath V, Nakase H, Panaccione R, Reinisch W, Verstockt B, Higgins PDR. New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC. Clinical Gastroenterology and Hepatology. Published online July 22, 2026. DOI: 10.1016/j.cgh.2026.07.011.

GastroAGI TeamRead more

6 min readJul 31, 202652reads

Smoking Cessation in Crohn's Disease: Why E-Cigarettes Belong in the Conversation

A 28-year-old woman with ileal Crohn's disease, two prior resections, and a pack-a-day habit tells you she's tried patches twice and lasted eleven days both times. She's not opposed to quitting. She's opposed to failing again. The conversation that follows determines whether she becomes one of the roughly 1 in 8 smokers with Crohn's disease who actually quit - or one of the majority who don't. Smoking is the single most consistently reproduced modifiable risk factor for a worse disease course in Crohn's disease, and gastroenterologists have known this for decades. What's changed is the toolkit. A 2026 JAMA Special Communication from the Treatment Research Network of the Society for Research on Nicotine and Tobacco now recommends that clinicians integrate nicotine e-cigarettes into shared decision-making conversations about smoking cessation in Crohn's disease, alongside FDA-approved pharmacotherapy - not instead of it. For a GI-specific population where relapse risk, not just cardiovascular or oncologic risk, hangs on quitting, this changes what "standard counseling" should look like at the point of care. The Clinical Problem: Counseling That Doesn't Match the Stakes Gastroenterologists already tell Crohn's disease patients to quit smoking. What most don't do is engage with why quit attempts fail, or offer a method beyond a pamphlet and a referral. The result is a gap between what we know about smoking cessation in Crohn's disease and what we actually do at the bedside. Nicotine replacement therapy has modest real-world quit rates, varenicline carries tolerability concerns some patients won't accept, and many patients arrive having already failed both. Meanwhile, nicotine e-cigarettes are misunderstood by clinicians almost as often as by patients - a persistent overestimation of relative harm that the JAMA authors argue is now out of step with the evidence. For a GI clinic seeing a patient with active or recent flares, this isn't an abstract public health issue. It's a modifiable variable sitting in the room. First Major Section: What Quitting Actually Buys a Crohn's Disease Patient The magnitude of benefit is the part worth stating plainly, because it's larger than most non-GI clinicians assume. In Cosnes and colleagues' intervention study, Crohn's disease patients who quit smoking for more than a year had a flare-up risk roughly two-thirds lower than those who continued, and their disease course converged with that of patients who had never smoked at all. Later work in the biologic era reproduced the same directional effect: continuing smokers had higher rates of corticosteroid use and intestinal resection, while quitters tracked with nonsmokers. This is not a modest risk reduction of the kind gastroenterologists are used to discounting. It rivals, and in some cohorts exceeds, the benefit of adding a biologic. The mechanism is still incompletely defined - proposed pathways include effects on mucosal microvascular perfusion, mucus composition, and innate immune signaling - but the clinical signal has been consistent since the 1990s. What has lagged is translating that signal into a structured cessation strategy embedded in routine Crohn's disease management, rather than a single line in the after-visit summary. Case in Point A 34-year-old man with stricturing ileocolonic Crohn's disease, on adalimumab, presents with his third flare in 18 months despite objective biologic drug levels in range and no evidence of antibody formation. He smokes 10–15 cigarettes daily, has tried nicotine gum twice, and describes the cravings as "worse than the disease some days." Rather than escalating therapy again, his gastroenterologist reframes the visit around smoking as an independent driver of his relapse pattern, separate from drug failure. The clinician walks through the relative-risk data directly - including that a nicotine e-cigarette is a reasonable option to raise alongside patch and gum, given his prior failures with both. The patient opts to try a nicotine e-cigarette under a structured taper plan with follow-up at four weeks. At three months, he's cigarette-free, still using the e-cigarette at a reduced nicotine concentration, and his biologic has been left unchanged rather than escalated to a second agent. Second Major Section: Building E-Cigarettes Into the Conversation Without Overselling Them The JAMA Special Communication's central recommendation is narrower than "recommend e-cigarettes" - it's to integrate them into a shared decision-making conversation that also covers NRT, varenicline, and bupropion, so the patient chooses with accurate information about relative risk rather than by default. For Crohn's disease patients specifically, that conversation should include three things most cessation scripts skip: the magnitude of GI-specific benefit from quitting, the fact that e-cigarettes deliver nicotine (still not risk-free, still relevant to a mucosal disease) without combustion products, and a plan for tapering off the e-cigarette itself rather than treating it as a permanent substitute. Two practical paths tend to work in a GI clinic that doesn't run its own tobacco program: refer to a structured cessation service and remain in the loop on whether e-cigarettes were part of that conversation, or manage the discussion directly and document a specific plan - product type, nicotine concentration, and a re-evaluation date - rather than a general instruction to quit. Patients who've already failed NRT twice are disproportionately the ones who benefit from having a different option named explicitly, rather than being sent back to the same failed method a third time. A Frequently Overlooked Point The instinct many gastroenterologists have is to treat smoking cessation as someone else's job - primary care's, pulmonology's, a quitline's - because IBD management already consumes the visit. But the relapse-risk data means that in a Crohn's disease patient who smokes, cessation counseling isn't adjacent to disease management; it functions as disease management, with an effect size comparable to therapy escalation. Deferring it to a specialty better equipped to run structured tobacco programs is reasonable. Deferring it indefinitely, or treating it as a single throwaway line at the end of a visit focused on drug levels and imaging, means missing the highest-yield intervention available for a meaningful subset of patients. Bottom Line for Clinical Practice Quote the Cosnes-era finding directly to patients: sustained smoking cessation cuts Crohn's disease flare risk by roughly two-thirds and brings the disease course in line with never-smokers. Before escalating biologic therapy for recurrent flares in a smoker, confirm whether a genuine cessation attempt, with a specific method and follow-up plan, has actually occurred. Offer nicotine e-cigarettes as one option within a shared decision-making conversation for patients who have already failed NRT or varenicline - not as a first-line default. Document product type, nicotine strength, and a taper timeline when e-cigarettes are chosen, and set a re-evaluation date rather than leaving the plan open-ended. Recognize that counseling quality, not counseling existence, predicts quit rates; a generic instruction to stop smoking performs far worse than a structured plan with a named method. Working through a Crohn's disease patient's relapse pattern and wondering how much of it is smoking-driven versus treatment failure? Walk GastroAGI through the case details - it will return a reasoned, guideline-anchored response in seconds.

GastroAGI TeamRead more

14 min readJul 30, 202639reads

Positive FIT Follow-Up: Why Completing Colonoscopy May Matter More Than Timing Alone

We count how many patients were invited for screening, how many returned a faecal immunochemical test, how many tests were positive, and how quickly colonoscopy appointments were offered. The more uncomfortable question is whether the patient actually reached the end of the pathway. A positive faecal immunochemical test, or positive FIT, is not a diagnosis. It does not confirm colorectal cancer, and it does not exclude it. It is a clinically important signal indicating that further evaluation—usually colonoscopy—is required. Yet discussions about positive FIT follow-up often become dominated by one question: How quickly should colonoscopy be performed? One month? Three months? Six months? Timing undoubtedly matters. However, the July 2026 Gut article, “Colonoscopy compliance matters more than time to colonoscopy after a positive FIT result,” asks clinicians and screening programmes to consider an even more fundamental issue: What is the value of rapid colonoscopy targets if a meaningful proportion of patients never undergo colonoscopy at all? The article was published online on July 24, 2026, by Adrien Grancher, Bernard Denis, and Lydia Guittet in Gut . Its DOI is 10.1136/gutjnl-2026-339212, and its PMID is 42498623. It should be read as a clinically important interpretive article rather than a new randomized trial. Its argument builds on an earlier French nationwide retrospective cohort study examining the relationship between time to colonoscopy after positive FIT and the detection of colorectal cancer, advanced-stage colorectal cancer, and advanced adenoma. The central message is not that timing is irrelevant. It is that colonoscopy completion is indispensable. A delayed colonoscopy remains an unfinished task. A colonoscopy that never happens is a failed diagnostic pathway. A positive FIT is a question, not an answer Patients sometimes understandably interpret a positive FIT as meaning that cancer has already been found. Others move in the opposite direction. Because they feel well, they assume the result cannot be particularly important. Neither interpretation is accurate. FIT detects faecal haemoglobin. It identifies people who need further investigation, but it cannot determine the underlying cause by itself. Colonoscopy is the step that allows clinicians to investigate for colorectal cancer and advanced precursor lesions. A positive FIT without subsequent diagnostic evaluation is therefore not completed screening. It is an unresolved clinical question. Consider an illustrative scenario. A 62-year-old patient receives a positive FIT result through an organised screening programme. The result is communicated, a referral is generated, and an appointment is offered. The patient postpones because of work commitments. The second appointment is missed because the bowel preparation instructions seemed confusing. A third letter is sent, but no direct contact occurs. From an administrative perspective, several actions have taken place. From a clinical perspective, almost nothing has been resolved. The test was completed. The pathway was not. This distinction lies at the heart of the July 2026 Gut article. Timing and compliance measure different failures Time to colonoscopy describes the interval between a positive FIT and colonoscopy among patients who undergo the procedure. Colonoscopy compliance describes whether the colonoscopy happens at all. These measures are related, but they are not interchangeable. A screening programme may report an impressive median waiting time while still losing a substantial number of FIT-positive patients before diagnostic completion. Conversely, another programme may have longer waiting intervals but successfully bring a larger proportion of patients to colonoscopy. The first programme looks efficient on a timing dashboard. The second may achieve more diagnostic closure. Medicine occasionally produces situations in which the prettier spreadsheet is not the safer service. The July 2026 article notes a colonoscopy compliance rate of 80% among individuals with a positive FIT in the context under discussion. That means a meaningful proportion of patients did not complete the expected diagnostic step. Every one of those patients remained at unresolved risk. This is why a positive FIT should not disappear into a referral queue after the result has been communicated. The clinically meaningful endpoint is not that a colonoscopy was recommended or booked. It is that the diagnostic evaluation was completed—or that a documented, clinically appropriate alternative decision was made. What the French nationwide cohort investigated The interpretive article builds on a French nationwide retrospective cohort study titled: “Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study.” The cohort included individuals with a positive FIT between 2016 and 2019 who subsequently underwent colonoscopy within 24 months. The exposure of interest was the interval from positive FIT to colonoscopy. The evaluated outcomes were: Colorectal cancer Advanced-stage colorectal cancer Advanced adenoma The study also examined individual and socio-geographic characteristics. The population was substantial. A total of 374,113 FIT-positive individuals underwent post-FIT colonoscopy, corresponding to an 86.6% compliance rate in the underlying cohort report. Among those individuals, investigators diagnosed: 21,616 colorectal cancers 122,359 advanced adenomas The scale of the study gives it important descriptive value within an organised national screening setting. However, the study was retrospective. It did not randomly assign patients to early or delayed colonoscopy. It also focused on individuals who ultimately underwent colonoscopy within 24 months. Those details are essential when interpreting the results. What the study found about colonoscopy timing Compared with colonoscopy performed within the 2–3 month interval, the study found no increased observed risk of colorectal cancer, advanced-stage colorectal cancer, or advanced adenoma among those undergoing colonoscopy after three months and up to 24 months. At 12 months, the adjusted odds ratios were: 0.93 for colorectal cancer 1.04 for advanced-stage colorectal cancer 0.88 for advanced adenoma At first glance, this may appear to suggest that timing does not matter. That would be an overinterpretation. The more accurate conclusion is narrower: Among FIT-positive individuals who eventually underwent colonoscopy within 24 months, longer intervals were not associated with a higher observed likelihood of colorectal cancer, advanced-stage colorectal cancer, or advanced adenoma compared with the 2–3 month interval. The study found no association within that population and setting. It did not prove that delaying colonoscopy is harmless for every patient. Those are not equivalent statements. Observational studies can describe patterns and associations. They cannot fully remove the possibility of confounding, selection bias, or systematic differences between patients scoped earlier and those scoped later. For example, clinicians may have prioritised patients with symptoms, higher faecal haemoglobin levels, significant anaemia, concerning medical history, or other risk features. Patients undergoing later colonoscopy may therefore differ from those undergoing earlier procedures in ways not fully reflected by the available data. The absence of a detected association should not be turned into permission for indefinite delay. Completion may matter more than shaving weeks from the waiting time The practical insight from the article is not that screening programmes should become relaxed about waiting periods. It is that programmes should distinguish between two different problems: A patient undergoes colonoscopy later than the preferred interval. A patient never undergoes colonoscopy. Both deserve attention, but the second represents complete loss of diagnostic follow-up. Imagine two screening services. In Service A, most patients receive a colonoscopy within six weeks, but one in five FIT-positive individuals never completes the procedure. In Service B, the average waiting time is somewhat longer, but almost every FIT-positive patient reaches diagnostic colonoscopy. This simplified scenario does not establish which service is better overall. Other factors—including cancer stage, procedure quality, patient risk, and capacity—would also matter. But it illustrates the article’s central argument: an excellent waiting-time target cannot compensate for patients disappearing from the pathway. Reducing an already scheduled patient’s wait by two weeks may be valuable. Finding the patient who was never successfully scheduled may be more valuable still. Faecal haemoglobin may help identify who needs greater urgency One of the most clinically useful findings from the underlying study concerns faecal haemoglobin concentration, often written as f-Hb. Patients with f-Hb concentrations of at least 200 µg/g were: Eight times more likely to have colorectal cancer Eleven times more likely to have advanced-stage colorectal cancer Twice as likely to have an advanced adenoma These comparisons were made against the 30–40 µg/g category. This finding reinforces a point that experienced clinicians already recognise conceptually: not every positive test carries identical risk. “Positive” is a threshold category. The quantitative result may contain additional clinical information. A patient with a markedly elevated f-Hb concentration may require greater urgency than someone with a lower-positive result, particularly when colonoscopy capacity is limited. This does not mean that lower-positive patients can safely be ignored. Every positive FIT still requires appropriate diagnostic follow-up. Instead, quantitative f-Hb may help screening programmes decide who should move closer to the front of the queue without allowing those further back to fall out of the queue altogether. The authors’ conclusion reflects this balance: colonoscopy completion may deserve priority over rigid interval adherence, while higher faecal haemoglobin concentrations support earlier colonoscopy. The mature interpretation is therefore: Completion is fundamental, but urgency should still respond to risk. A booked colonoscopy is not a completed colonoscopy Healthcare systems often treat scheduling as evidence of progress. Clinically, however, an appointment date is only a promise. It does not diagnose colorectal cancer, remove an advanced adenoma, or explain a positive FIT result. Patients may fail to complete colonoscopy for many reasons: Fear of the procedure Anxiety about a possible cancer diagnosis Difficulty understanding bowel preparation Transport limitations Work or caregiving responsibilities Financial concerns Medical comorbidity Poor communication Referral delays Fragmented responsibility between services Previous unpleasant procedural experiences Some patients do not actively refuse colonoscopy. They simply become lost between a positive test, a referral, an appointment letter, and a complex healthcare system. This is why active tracking matters. A screening programme should ideally know whether each FIT-positive patient: Completed colonoscopy Declined after informed discussion Was medically unsuitable Chose an alternative pathway Remains awaiting the procedure Was lost to follow-up The phrase “colonoscopy advised” is not diagnostic closure. Nor, unfortunately, is “patient did not attend” a complete clinical strategy. What clinicians can do differently The article’s message has practical implications for gastroenterologists, primary care clinicians, endoscopy services, and screening-programme leaders. Track patients until the pathway is resolved A positive FIT should trigger follow-up that continues until colonoscopy is completed or another documented clinical decision is reached. Responsibility should not become ambiguous after referral. When everyone assumes someone else is following the patient, the patient may discover that nobody is. Identify barriers before the appointment Patients may miss colonoscopy because they do not understand why it is required, fear the preparation, cannot arrange transport, or believe absence of symptoms means absence of risk. A short, clear conversation can reveal barriers that an automated letter will not. For example: “You have a positive screening test. This does not mean you have cancer, but it does mean we need colonoscopy to understand why the test was positive.” That explanation is simple, accurate, and often more useful than several paragraphs of institutional language. Use risk information intelligently Quantitative f-Hb may help prioritise patients when demand exceeds immediate colonoscopy capacity. Higher-risk patients may need faster access, but the system must still protect lower-priority patients from non-completion. Risk stratification should organise follow-up, not justify abandonment. Measure completion as a quality outcome Time-to-colonoscopy remains important, but screening programmes should also report: Colonoscopy completion rate Reasons for non-completion Time from positive FIT to diagnostic resolution Missed appointment recovery Variation across geographic or socioeconomic groups Completion according to f-Hb category Cancer and advanced adenoma detection A service cannot improve a failure it does not measure. Why this matters when colonoscopy capacity is limited Many screening systems operate under capacity pressure. There may be more positive FIT results than immediately available colonoscopy slots. Endoscopy lists may already contain symptomatic referrals, surveillance procedures, therapeutic cases, urgent bleeding, and patients requiring complex support. The response to limited capacity cannot be to pretend every patient can be scoped instantly. Nor should the response be to accept prolonged waits without scrutiny. The article supports a more intelligent use of resources. Programmes should aim to: Complete colonoscopy for all eligible FIT-positive patients Prioritise those at higher risk Prevent missed appointments from becoming permanent loss to follow-up Simplify referral and scheduling Improve bowel-preparation support Communicate the significance of positive FIT clearly Monitor both waiting time and completion There is little value in creating an exceptionally fast pathway for patients who are already engaged while failing to recover those who have quietly fallen out of the system. Efficiency is not only about moving quickly. It is also about making sure the right patients arrive. What this evidence should not be used to claim The study should not be presented as evidence that colonoscopy can safely be postponed for up to 24 months in every FIT-positive individual. It should not be used to reassure patients that delay carries no risk. It should not be interpreted as a recommendation to weaken existing national or local screening guidance. It should not be described as proving that early and late colonoscopy are clinically equivalent. The underlying evidence was observational, not randomized. The study population consisted of patients who ultimately underwent colonoscopy within 24 months. Differences between earlier and later groups may have influenced the observed findings. The article’s title is deliberately provocative, but its message is not an invitation to complacency. It is a reminder to focus on the entire pathway. “Compliance matters more” does not mean “time does not matter.” It means that discussing optimal timing becomes rather theoretical when the colonoscopy never occurs. Strengths of the evidence The underlying cohort has several important strengths. First, it was large, including more than 374,000 FIT-positive individuals who underwent colonoscopy. Second, it was embedded within a national screening context, giving it relevance for programme-level planning. Third, it examined meaningful clinical outcomes rather than waiting times alone: Colorectal cancer Advanced-stage colorectal cancer Advanced adenoma Fourth, it incorporated quantitative faecal haemoglobin, providing clinically useful information for risk stratification. Finally, the July 2026 Gut article draws attention to a quality measure that can be overshadowed by timing targets: whether diagnostic colonoscopy was completed. Important limitations The most important limitation is the retrospective observational design. Time to colonoscopy was not assigned randomly. Earlier and later groups may have differed in symptoms, clinical urgency, f-Hb concentration, geography, healthcare access, comorbidity, or other factors. The cohort also included individuals who completed colonoscopy within 24 months. Patients who never underwent colonoscopy are central to the compliance question, but their colonoscopy-detected outcomes cannot be evaluated in the same manner. The findings arose from a particular French national screening setting. Other countries may use different FIT thresholds, referral systems, colonoscopy capacity, navigation processes, and reporting standards. The July 2026 article is also not a guideline. It can inform clinical thinking and quality improvement, but it should not replace national screening recommendations or local policy. What future research should examine Future research should move beyond describing non-completion and test interventions designed to prevent it. Relevant strategies may include: Patient-navigation programmes Direct colonoscopy scheduling Reminder systems Primary care follow-up Simplified referral pathways Bowel-preparation education Transport support Multilingual communication Outreach after missed appointments Risk-based triage using quantitative f-Hb Research should also examine whether prioritisation based on faecal haemoglobin improves outcomes without creating inequity. A risk-based system may be clinically sensible, but it must not create a lower-priority group that becomes an invisible group. Future studies should report both time to colonoscopy and colonoscopy completion. One without the other provides an incomplete picture. Timing tells us how quickly the system moved. Completion tells us whether the system arrived. Clinical Takeaway The July 2026 Gut article “Colonoscopy compliance matters more than time to colonoscopy after a positive FIT result” highlights a fundamental principle of colorectal cancer screening: A positive FIT only creates benefit when the diagnostic pathway is completed. The underlying French nationwide retrospective cohort included 374,113 FIT-positive individuals who underwent colonoscopy within 24 months. Longer intervals beyond three months were not associated with a higher observed risk of colorectal cancer, advanced-stage colorectal cancer, or advanced adenoma compared with colonoscopy at 2–3 months. However, this finding does not prove that delay is harmless, nor does it support postponing colonoscopy intentionally. Higher faecal haemoglobin concentrations identified patients with substantially greater likelihood of colorectal cancer, advanced-stage disease, and advanced adenoma, supporting risk-based prioritisation when resources are constrained. The most balanced clinical interpretation is straightforward: Positive FIT follow-up should be timely, but above all, it must be completed. For screening programmes, the meaningful endpoint is not a test result, a referral letter, or an appointment date. It is diagnostic resolution. Five Key Clinical Takeaways The July 2026 Gut article argues that completing colonoscopy after positive FIT may be more important than focusing exclusively on rigid timing targets. The underlying French nationwide retrospective cohort included 374,113 FIT-positive individuals who underwent colonoscopy within 24 months. Longer intervals up to 24 months were not associated with a higher observed risk of colorectal cancer, advanced-stage colorectal cancer, or advanced adenoma compared with the 2–3 month interval. An f-Hb concentration of at least 200 µg/g was associated with substantially higher likelihood of colorectal cancer, advanced-stage colorectal cancer, and advanced adenoma compared with the 30–40 µg/g category. The evidence supports stronger tracking, navigation, risk-based prioritisation, and colonoscopy-completion systems—not deliberate delay or departure from established screening guidance. Source Reference Grancher A, Denis B, Guittet L. Colonoscopy compliance matters more than time to colonoscopy after a positive FIT result. Gut. Published online July 24, 2026. DOI: 10.1136/gutjnl-2026-339212. PMID: 42498623. Related underlying cohort: Grancher A, Denis B, Plaine J, Vidal-Sengchanh S, Quertier M-C, Quintin C, Guittet L. Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study. Gut.

GastroAGI TeamRead more

14 min readJul 30, 2026159reads

2026 ESGE–ESGENA Sedation Guideline for GI Endoscopy: Practical Lessons for Safer Clinical Practice

After 25 years in gastroenterology, I have learned that the word routine deserves cautious handling. A routine colonoscopy may suddenly become technically difficult. A routine upper gastrointestinal endoscopy may encounter an unexpected bleeding lesion. A patient who looked perfectly comfortable in the assessment area may become hypoxic shortly after sedation begins. Sedation itself is often described as routine. In practice, it is anything but trivial. When sedation works well, almost nobody notices it. The patient is comfortable, the endoscopist can concentrate, the nursing team remains calm, and recovery proceeds without incident. When sedation is poorly planned, however, it can dominate the entire procedure. The newly published “Sedation for gastrointestinal endoscopy: ESGE and ESGENA Guideline” places this familiar but safety-critical part of endoscopy back where it belongs: at the centre of procedural planning. The guideline was published online on July 21, 2026 , in Endoscopy by the European Society of Gastrointestinal Endoscopy (ESGE) and the European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) . Its DOI is 10.1055/a-2898-6540 . This is a professional society guideline rather than a clinical trial. There is no randomized treatment arm, comparator group, predefined patient population, or single outcome measure. Instead, the document is intended to guide the safe organization and delivery of sedation across gastrointestinal endoscopy services. That distinction matters. Guidelines rarely provide the dramatic headline of a positive randomized trial. Their value is quieter but often broader: they help clinicians examine whether everyday practice is as safe, consistent, and defensible as it should be. The sedative is only one part of sedation safety When discussing endoscopy sedation, conversations frequently begin with the drug. Which agent should be used? How much should be given? Who should administer it? These are important questions, but they are not the whole story. Sedation safety begins before the medication is drawn up and continues long after the endoscope has been removed. It includes: Pre-procedure risk assessment Patient selection Informed consent Procedure-specific planning Appropriate staffing Physiological monitoring Airway preparedness Recognition of deterioration Recovery supervision Discharge assessment Documentation Post-procedure instructions In other words, sedation is not a syringe. It is a clinical pathway. Consider two patients scheduled on the same list. The first is a healthy 42-year-old undergoing diagnostic gastroscopy for dyspepsia. The second is a frail 79-year-old with cardiopulmonary disease, possible obstructive sleep apnea, and a prolonged therapeutic procedure planned. Both are attending for gastrointestinal endoscopy. That does not mean they have the same sedation needs. A safe service does not ask only, “What sedation do we normally give for this procedure?” It asks, “What level of sedation risk does this particular patient bring to this particular procedure in this particular setting?” The repetition is intentional. Sedation decisions should be individualized, not inherited from habit. Why a new endoscopy sedation guideline matters in 2026 Modern endoscopy is not the same service it was two decades ago. Diagnostic procedures remain central, but the field has become increasingly interventional. Endoscopic resection, advanced pancreatobiliary procedures, EUS-guided interventions, bariatric endoscopy, foreign body removal, emergency haemostasis, and complex therapeutic procedures may require longer procedure times, greater patient immobility, and more controlled operating conditions. At the same time, the patients arriving in endoscopy units are often older and medically more complex. The endoscopist may therefore face a familiar clinical tension: the procedure requires stable conditions, but deeper or prolonged sedation may increase risk in precisely the patient who most needs the procedure. This is why sedation cannot be reduced to a standard medication protocol attached to a procedure name. A planned ERCP in a medically fit patient, an urgent endoscopy for gastrointestinal bleeding, and an advanced resection in a frail individual may all involve different considerations. The appropriate approach depends on the patient’s condition, procedure complexity, anticipated duration, team competence, monitoring capacity, and availability of additional support. The 2026 ESGE–ESGENA sedation guideline is timely because it encourages clinicians and endoscopy units to review sedation as part of endoscopy-service quality, not merely patient comfort. Comfort matters greatly. But comfort without safety is not a successful sedation strategy. A guideline about teamwork, not professional territory One of the most meaningful features of the guideline is the collaboration between ESGE and ESGENA. Sedation is delivered within a team. The endoscopist may lead the procedure, but safe sedation also depends on the vigilance, training, communication, and judgment of nursing staff, recovery personnel, anesthesia colleagues, and the wider endoscopy service. Anyone who has worked in a busy endoscopy unit knows that deterioration is not always announced dramatically. It may begin with a subtle change in respiratory pattern, a declining oxygen saturation, altered responsiveness, or simply an experienced nurse saying, “This patient does not look quite right.” That sentence has prevented more trouble than many sophisticated devices. The involvement of ESGENA reinforces an important truth: nursing observation, monitoring, documentation, recovery assessment, and escalation are not secondary functions. They are central components of sedation safety. The guideline should therefore not be interpreted as a debate about which professional group “owns” sedation. Patients are rarely impressed by territorial arguments. They expect the entire team to recognize risk, communicate clearly, and respond appropriately. The more useful question is whether the chosen sedation model matches: Patient risk Procedure complexity Staff training Monitoring resources Rescue capability Local regulations Access to anesthesia support From comfort medication to procedural risk management For many clinicians, the most valuable shift may be conceptual. Sedation is often framed primarily as a way to improve comfort and tolerance. That is correct, but incomplete. Sedation is also a form of procedural risk management . The sedation plan can affect whether the procedure can be completed, whether the patient remains physiologically stable, whether the endoscopist can work safely, and whether the team can respond rapidly if complications occur. Imagine a technically demanding endoscopic procedure expected to last considerably longer than routine diagnostic endoscopy. The patient becomes restless, sedation is repeatedly increased, monitoring becomes more difficult, and the team gradually moves from a planned strategy to reactive medication administration. This is a common type of scenario—not because the team lacks skill, but because the sedation requirements may not have been fully anticipated. Good sedation planning attempts to solve that problem before it develops. The correct question is not simply whether the patient can tolerate the first five minutes of the procedure. It is whether the planned sedation model remains appropriate throughout the expected duration and complexity of the intervention. That requires foresight, not merely familiarity with sedative drugs. Pre-procedure assessment should change the plan when necessary A pre-endoscopy assessment becomes meaningful only when its findings are capable of changing management. Recording age, comorbidities, medication exposure, cardiopulmonary status, frailty, aspiration risk, and possible obstructive sleep apnea has limited value if every patient then receives the same pathway. The purpose of assessment is risk recognition. For example, suppose a patient is listed for an apparently straightforward procedure but has significant respiratory disease, reduced physiological reserve, and features suggesting sleep-disordered breathing. The correct response is not necessarily to cancel the procedure or automatically request anesthesia involvement. Nor is it to ignore the findings because “we use this sedation every day.” The findings should trigger a structured decision: Is the planned level of sedation appropriate? Is the setting adequately equipped? Is enhanced monitoring required? Is additional support advisable? Should the procedure be modified or rescheduled? Is the anticipated benefit sufficient to justify the sedation risk? Guidelines are most useful when they improve these decisions before the patient enters the procedure room. Different procedures create different sedation demands A diagnostic upper GI endoscopy, screening colonoscopy, therapeutic ERCP, EUS-guided intervention, endoscopic resection, bariatric procedure, foreign body retrieval, or emergency haemostasis should not automatically be approached as variations of the same sedation problem. Procedure complexity matters. Expected duration matters. Patient positioning matters. The likelihood of discomfort, immobility requirements, aspiration concerns, and the potential need for urgent intervention all matter. In practice, procedure lists often encourage standardization because standardization improves efficiency. But safe standardization should create reliable pathways, not erase clinically important differences. There is a difference between a protocol and an autopilot. A good protocol ensures that the same relevant questions are asked for every patient. Autopilot assumes the answers will always be the same. Monitoring is not simply a documentation exercise Monitoring sometimes becomes so familiar that it risks being treated as a collection of numbers that must appear in the record. That is not its purpose. The purpose of monitoring is to identify physiological change early enough for the team to act before deterioration becomes difficult to reverse. A monitor displaying reassuring values does not replace direct clinical observation. Equally, clinical observation alone may not detect every developing problem promptly. Safe sedation depends on integrating both. The exact monitoring requirements, thresholds, and procedure-specific recommendations should be taken from the complete guideline and interpreted according to local practice and regulations. However, the broader principle is clear: monitoring must be appropriate to the patient, the planned sedation depth, and the procedure being performed. It should also be accompanied by a predefined response. Detecting deterioration without having trained staff, airway equipment, escalation protocols, or rescue capability is similar to installing a smoke alarm without considering how people will leave the building. The alarm is helpful. The response system is what saves the situation. Recovery is still part of the procedure Endoscopists naturally focus on the period during which the endoscope is inside the patient. Sedation does not respect that boundary. A procedure may be technically complete while the patient remains under the physiological effects of sedation. Recovery assessment therefore deserves the same seriousness as pre-procedure assessment and intraprocedural monitoring. Patients must be observed appropriately, assessed against defined discharge criteria, and given clear instructions. A patient opening their eyes and asking for tea is encouraging. It is not, by itself, a validated discharge strategy. Endoscopy units should have consistent recovery and discharge processes rather than relying solely on informal impressions. The patient’s level of alertness, physiological stability, mobility where relevant, supervision arrangements, and understanding of post-procedure advice may all affect safe discharge. Again, the detailed criteria should be taken from the complete guideline and local policy. The broader message is that the sedation pathway ends only when recovery has been assessed properly and responsibility has been transferred safely. What experienced clinicians should reconsider Experience is invaluable in endoscopy, but it carries one occupational hazard: familiar practice can begin to feel equivalent to best practice. They are not always the same. A clinician may have administered sedation in a particular way for many years without encountering a major event. That experience is reassuring, but it does not remove the need to review current guidance. Absence of a previous complication does not prove that the system is optimally designed. It may reflect good practice, fortunate patient selection, skilled staff, or simply the rarity of serious events. The mature clinical approach is not to reject guidelines because experience exists. Nor is it to abandon judgment in favour of rigid rules. The better approach is to place experience in conversation with current guidance. Guidelines show what contemporary evidence and expert consensus suggest. Experienced clinicians understand how recommendations behave in real units, with real staffing limitations, real patients, and the occasional endoscopy list that appears to have been organized by someone with a personal objection to lunch. Both perspectives are needed. What fellows and trainees should learn from the guideline Trainees understandably focus on scope handling, lesion recognition, cannulation, biopsy technique, polypectomy, haemostasis, and resection skills. Sedation can appear to sit in the background—until it suddenly becomes the main clinical problem in the room. A well-trained endoscopist should understand not only how to perform the procedure but also when the proposed sedation plan is unsuitable. This includes recognizing: High-risk patients Procedures likely to be prolonged Situations requiring additional support Early signs of sedation-related deterioration When the procedure should be paused When escalation is necessary When patient safety should take priority over procedural completion There is no technical prize for completing an endoscopy that should have been stopped. Judgment includes knowing when not to proceed, when to modify the plan, and when to ask for help. The ESGE guideline list also includes an earlier ESGE–ESGENA position statement addressing sedation training in gastrointestinal endoscopy. This reinforces the idea that sedation is a formal competency, not something trainees should absorb casually by watching how different supervisors happen to work. Questions every endoscopy unit should now ask The most practical response to the 2026 ESGE–ESGENA endoscopy sedation guideline is a local audit. Unit leaders and clinical teams should examine whether their present system answers the following questions clearly: Is there a written sedation policy? Are patients assessed consistently before endoscopy? Are high-risk patients identified early? Does procedure complexity influence sedation planning? Are expected duration and therapeutic demands considered? Are monitoring responsibilities clearly assigned? Are observations documented consistently? Can staff recognize early sedation-related deterioration? Is airway rescue equipment immediately available? Are escalation pathways defined? Is anesthesia support requested according to clear clinical criteria? Are recovery and discharge standards consistent? Are staff competencies reviewed and updated? Are sedation-related adverse events audited? The point is not to create paperwork for its own sake. The point is to ensure that safety does not depend entirely on which clinician, nurse, or recovery staff member happens to be working that day. Reliable systems protect patients and professionals alike. What clinicians should not claim from the available source This article remains deliberately cautious because the accessible source confirms the guideline’s identity and publication details but does not present the complete recommendation text. The guideline should not be described as proving that one sedation model reduces mortality, improves adenoma detection, increases cannulation success, improves completion rates, or produces better patient satisfaction unless those conclusions are explicitly supported in the full document. Similarly, the accessible source does not justify claiming that the guideline mandates: One universal sedative drug One sedation-provider model Anesthesia involvement for every advanced procedure A single monitoring threshold A universal staffing ratio One discharge scoring system A procedure-specific algorithm applicable to every setting Those details must be checked in the full ESGE–ESGENA guideline. Clinical interpretation must also account for local regulations, available personnel, institutional policy, procedure volume, patient characteristics, and access to anesthesia services. A European guideline can inform practice internationally, but implementation should not ignore the realities of the local healthcare environment. Strengths of the 2026 ESGE–ESGENA guideline The guideline has several important strengths. First, it comes from ESGE and ESGENA, bringing together medical endoscopy and nursing perspectives. Second, it addresses a high-frequency clinical issue relevant to virtually every gastrointestinal endoscopy service. Third, it is positioned within endoscopic service guidance rather than being restricted to one disease or procedure category. Fourth, its 2026 publication provides a contemporary opportunity to reassess sedation practice as endoscopy becomes increasingly complex and patient populations become older and more medically vulnerable. Finally, the guideline encourages a systems-based view of sedation. This is important because adverse events rarely result from one decision alone. They often arise from an interaction between patient vulnerability, procedure demands, medication effects, monitoring, communication, staffing, and delayed escalation. Limitations of this interpretation This blog uses only information supported by the accessible source. The source confirms: The full guideline title ESGE and ESGENA involvement Publication in Endoscopy Online publication on July 21, 2026 DOI 10.1055/a-2898-6540 Its position within ESGE endoscopic service guidance The accessible page does not provide the full graded recommendations. Therefore, this article does not attempt to reproduce detailed guidance on medication selection, exact dosing, monitoring thresholds, staffing requirements, discharge scores, or procedure-specific sedation pathways. Clinicians and endoscopy-unit leaders should consult the complete guideline before changing formal protocols. This article is intended to explain why the guidance matters and how an experienced clinician might approach it—not to replace the original document. Clinical Takeaway The 2026 ESGE–ESGENA guideline on sedation for gastrointestinal endoscopy should encourage every endoscopy service to examine sedation as a complete patient-safety pathway. The central lesson is not that one sedation technique is correct for every patient. It is that sedation should be planned according to: Individual patient risk Procedure complexity Expected duration Required sedation depth Team competence Monitoring capability Recovery resources Availability of escalation and rescue support For gastroenterologists, sedation should be understood not merely as a way to make endoscopy tolerable, but as a form of procedural risk management. For trainees, it should be treated as a formal clinical competency. For endoscopy nurses and recovery teams, the guideline reinforces their central role in monitoring, communication, deterioration recognition, and safe discharge. For unit leaders, the practical next step is an audit: Are sedation decisions systematic, individualized, documented, monitored, and supported by trained staff? If the answer is uncertain, the guideline has already served a useful purpose. After all, the safest endoscopy units are not those that assume complications will never occur. They are the ones that have thought carefully about what to do when the routine procedure stops being routine. Five Key Clinical Takeaways The 2026 ESGE–ESGENA sedation guideline was published online in Endoscopy on July 21, 2026 , with DOI 10.1055/a-2898-6540 . It is a professional society guideline, not a clinical trial, and should not be presented as generating new randomized patient-level outcome data. Sedation should be viewed as a complete pathway involving pre-assessment, individualized planning, monitoring, rescue readiness, recovery, discharge, documentation, and training. The ESGE–ESGENA collaboration highlights the central role of multidisciplinary teamwork, particularly endoscopy nursing, monitoring, recovery, and escalation processes. Clinicians should use the complete guideline to review local sedation policies while avoiding claims about specific drugs, provider models, monitoring thresholds, or clinical outcomes that are not confirmed by the full document. Source Reference Triantafyllou K, Tziatzios G, Tham TC, Beilenhoff U, Lorenzo-Zúñiga V, Pouw RE, Roelandt P, van Malenstein H, Vilmann P, Voiosu T, Abu-Freha N, Becq A, Coron E, Garborg K, Hollenbach M, Kovacevic B, Manno M, Parrella A, Pontone S, Romańczyk M, Sá PA, Soria San Teodoro MT, Turnbull D, Sidhu R. Sedation for gastrointestinal endoscopy: ESGE and ESGENA Guideline. Endoscopy. Published online July 21, 2026. DOI: 10.1055/a-2898-6540 . Source: ESGE guideline page.

GastroAGI TeamRead more

11 min readJul 30, 202644reads

Ustekinumab for Fistulising Perianal Crohn’s Disease: What the GETAID Trial Adds to Clinical Practice

For many gastroenterologists, fistulising perianal Crohn’s disease represents one of the most difficult phenotypes to manage: not because the problem is rare in specialist practice, but because clinical decision-making often requires acting with imperfect evidence. The therapeutic goal is not simply improvement in luminal inflammation. Clinicians must also address persistent drainage, recurrent sepsis risk, patient discomfort, repeated imaging, surgical coordination, and the uncertainty of whether apparent external closure reflects durable internal healing. Against this background, the GETAID trial of ustekinumab provides an important and clinically focused contribution. Published online in Gut on July 24, 2026, the article is titled “Ustekinumab for fistulising perianal Crohn’s disease: a randomised placebo-controlled trial from the GETAID.” The study was a double-blind, multicentre, randomised placebo-controlled trial evaluating ustekinumab in patients with Crohn’s disease and active draining perianal fistulas. The key question is direct and practice-relevant: in patients with active fistulising perianal Crohn’s disease, does ustekinumab improve combined clinical and radiological remission compared with placebo after standardised surgical management? Why this trial matters in a phenotype with limited RCT evidence The source article itself frames fistulising perianal Crohn’s disease as a debilitating condition with few randomised controlled trials conducted to date. That point is central to how clinicians should interpret the study. Much of perianal Crohn’s care has historically relied on a combination of extrapolation from luminal Crohn’s disease trials, subgroup analyses, real-world cohorts, and multidisciplinary experience. Those sources are valuable, but they do not replace placebo-controlled evidence in a population defined by active draining perianal fistulas. This trial is therefore not just another biologic study. It is an attempt to evaluate ustekinumab in a clinically specific phenotype, using outcomes that acknowledge both bedside examination and pelvic imaging. That distinction matters because perianal fistula assessment can be misleading if based only on external drainage. Absence of drainage may be clinically encouraging, but persistent abscess or ongoing deep tract activity on MRI may still carry clinical significance. The GETAID trial’s primary endpoint was deliberately composite: combined clinical remission, defined as absence of drainage from all external fistula openings, and radiological remission, defined as absence of abscesses larger than 2 cm on blinded central MRI, at week 12. This design choice makes the endpoint more stringent than a purely clinical drainage measure and more relevant to clinicians who manage perianal disease in collaboration with colorectal surgeons and radiologists. Study design: targeted, controlled, and clinically recognisable The trial enrolled patients with active fistulising perianal Crohn’s disease and randomised them 1:1 to ustekinumab or placebo after standardised surgical management. The ustekinumab regimen consisted of 6 mg/kg intravenously at baseline, followed by 90 mg subcutaneously at week 8 and then every 8 weeks. The study was multicentre and double-blind, conducted across 10 French centres under the Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives, or GETAID. Thirty-two patients were randomised: 16 to ustekinumab and 16 to placebo. The population was clinically challenging: 69% had prior anti-tumour necrosis factor failure. This population detail is particularly important. A trial enriched with patients who have already failed anti-TNF therapy addresses a common real-world dilemma: what to do when first-line biologic strategies for fistulising perianal Crohn’s disease have not delivered adequate control. However, the same detail also affects interpretation. Outcomes in a previously anti-TNF-exposed population may not translate directly to biologic-naïve patients, and the small sample size limits confidence in subgroup-level conclusions. The trial also included an open-label phase. At week 12, placebo non-responders could switch to ustekinumab, and ustekinumab non-responders could undergo treatment intensification during the open-label phase. This feature is clinically understandable, especially in a symptomatic fistulising disease population, but it complicates longer-term comparisons between the original randomised arms. The week-12 signal: better combined remission with ustekinumab At week 12, combined remission was achieved in 62% of patients receiving ustekinumab compared with 25% receiving placebo. The reported odds ratio was 5.1, with a 95% confidence interval of 1.07 to 24.4. This is the central efficacy signal of the trial. The direction of effect favoured ustekinumab, and the outcome was clinically meaningful because it combined absence of drainage from external openings with MRI-based absence of abscesses larger than 2 cm. The finding suggests that ustekinumab may provide short-term benefit in active fistulising perianal Crohn’s disease after standardised surgical management. The width of the confidence interval should be read carefully. A confidence interval from 1.07 to 24.4 reflects substantial uncertainty around the magnitude of effect, which is expected in a small trial with 32 randomised patients. The result supports a treatment signal but does not precisely define the size of benefit clinicians should expect in broader practice. Clinical remission alone occurred in 62.5% of the ustekinumab group compared with 31% of the placebo group, with an odds ratio of 3.75 and a 95% confidence interval of 0.84 to 16.8. Radiological remission occurred in 87.5% versus 75%, with an odds ratio of 2.7 and a 95% confidence interval of 0.34 to 21.1. These secondary outcomes are useful but should not be overinterpreted. The point estimates favour ustekinumab, but the confidence intervals are wide and include uncertainty. For practicing clinicians, the most defensible reading is that the composite week-12 endpoint provides the clearest positive signal, while the separate clinical and radiological components should be viewed as supportive but imprecise. Why the composite endpoint is clinically meaningful Perianal Crohn’s disease is not adequately captured by one measure. Drainage reflects the patient-facing and examination-facing burden of disease. MRI provides information about deeper inflammatory complications, particularly abscess. By combining both, the trial attempted to avoid the pitfall of mistaking external closure for complete disease control. The radiological component used a pragmatic threshold: absence of abscesses larger than 2 cm on blinded central MRI. This does not necessarily mean complete anatomical healing of all fistula tracts. It means that, within the trial definition, radiological remission required absence of a clinically relevant abscess threshold. Clinicians should therefore avoid describing the primary endpoint as complete fistula healing unless they define exactly what was measured. This distinction is more than semantic. Patients may ask whether a treatment “heals the fistula.” The trial supports a short-term improvement in a combined clinical and MRI-based endpoint, not a universal guarantee of durable fistula closure or elimination of future surgical need. The source details available do not justify claims about complete tract resolution, long-term prevention of recurrence, or superiority over other active biologics. Interpreting the week-48 findings without overstating durability The open-label phase provides additional context but less controlled evidence than the double-blind week-12 comparison. Nine placebo-group patients switched to ustekinumab during the open-label phase. Combined remission rates at week 48 were reported as 50% in the placebo arm and 31% in the ustekinumab arm. These week-48 figures should be interpreted cautiously. Because non-responders could switch or intensify after week 12, the original randomised comparison becomes less straightforward. The lower week-48 combined remission rate in the original ustekinumab arm should not be read in isolation as evidence of loss of efficacy, nor should the 50% rate in the placebo arm be interpreted as placebo superiority. Treatment switching and intensification alter the meaning of arm-level comparisons. The most reliable inference remains the short-term randomised comparison at week 12. The longer-term data raise important clinical questions about durability, optimisation, timing of intensification, and the role of ongoing surgical or imaging-based management, but they do not provide a clean placebo-controlled maintenance comparison. What clinicians can reasonably conclude The authors concluded that the findings suggest greater short-term clinical benefit with ustekinumab compared with placebo and support its use in patients with active fistulising perianal Crohn’s disease. That conclusion is appropriately measured. It does not claim that ustekinumab is curative, that it replaces surgical management, or that it should be considered definitively superior to other biologic strategies. For gastroenterologists, the trial strengthens the evidence base for considering ustekinumab in active fistulising perianal Crohn’s disease, particularly in a population where many patients had prior anti-TNF failure. It also reinforces the importance of multidisciplinary management, because patients entered the trial after standardised surgical management. The medical therapy signal should therefore be understood as occurring within a structured care pathway rather than as isolated biologic treatment. This is not evidence that ustekinumab should be used without adequate assessment for abscess, seton need, or surgical input. It is also not a direct comparison with anti-TNF therapy, vedolizumab, IL-23 inhibitors, antibiotics, stem-cell therapy, or surgical approaches. The trial compared ustekinumab with placebo under the trial protocol. What clinicians should not conclude Several conclusions would go beyond the source. First, the trial does not establish ustekinumab as the best biologic for fistulising perianal Crohn’s disease. No active comparator was included. A placebo-controlled design answers whether ustekinumab performs better than placebo under study conditions; it does not rank ustekinumab against other treatments. Second, the trial does not prove that ustekinumab prevents recurrence, avoids surgery, or reduces hospitalisation. Those outcomes are not supported by the source details available. Third, the trial should not be presented as definitive for all patients with perianal Crohn’s disease. The sample was small, and most patients had prior anti-TNF failure. The findings may be most relevant to a specialist population with active draining disease managed in experienced centres. Fourth, clinicians should not infer that week-48 arm-level results provide a simple maintenance efficacy estimate. The open-label crossover and intensification design makes those later outcomes clinically informative but methodologically less definitive than the week-12 endpoint. Strengths that make the study clinically useful Several features increase the value of the GETAID trial. The study was randomised, double-blind, placebo-controlled, and multicentre. It focused specifically on active draining fistulising perianal Crohn’s disease rather than treating perianal disease as a small subgroup within a luminal Crohn’s trial. It used a clinically meaningful composite endpoint that incorporated both external drainage and blinded central MRI assessment for abscess. It also embedded treatment after standardised surgical management, reflecting the multidisciplinary reality of perianal Crohn’s care. The inclusion of a high proportion of patients with prior anti-TNF failure is another clinically relevant feature. These are precisely the patients in whom clinicians often need additional evidence to support treatment selection. Limitations that should shape practice interpretation The most obvious limitation is size. Thirty-two randomised patients is a small trial, particularly for a heterogeneous condition such as fistulising perianal Crohn’s disease. Small trials can detect important signals, but they are vulnerable to imprecision. The wide confidence intervals around several outcomes reflect that uncertainty. Second, the open-label phase limits clean interpretation of longer-term outcomes. Crossover and intensification are ethically and clinically understandable but reduce the ability to interpret week-48 arm comparisons as a sustained randomised treatment effect. Third, the available source details do not provide enough information to make claims about specific fistula anatomy, quality of life, adverse event patterns, need for further procedures, or long-term recurrence. Those may be addressed in the full article, but they should not be invented or assumed from the abstract-level information. Fourth, the trial’s findings apply to the studied intervention and protocol: intravenous induction followed by subcutaneous maintenance dosing after standardised surgical management. Extrapolation to different dosing strategies, earlier use, combination approaches, or non-specialist settings requires caution. How this may influence future research The GETAID trial strengthens the rationale for larger, phenotype-specific trials in perianal Crohn’s disease. Future studies should clarify durability, optimal timing of biologic initiation relative to surgical control, the value of dose intensification, predictors of response, MRI-based definitions of deeper healing, and patient-centred outcomes such as pain, drainage burden, continence concerns, work impairment, and quality of life. The trial also highlights the need for standardised endpoints. A combined clinical-radiological endpoint may be more clinically meaningful than drainage alone, but future research should continue refining what constitutes true healing, meaningful improvement, and durable remission in fistulising disease. Clinical Takeaway The GETAID ustekinumab trial provides a focused, randomised placebo-controlled signal that ustekinumab improves short-term combined clinical and radiological remission in active fistulising perianal Crohn’s disease after standardised surgical management. The week-12 composite remission rate favoured ustekinumab, but the small sample size and wide confidence intervals mean the magnitude of benefit remains uncertain. Longer-term data are clinically interesting but harder to interpret because of open-label crossover and treatment intensification. For clinicians, the study supports ustekinumab as an evidence-backed option in this difficult phenotype, especially when anti-TNF failure has occurred. It should not be framed as definitive proof of durable fistula healing, superiority over other therapies, or replacement for multidisciplinary surgical assessment. The most responsible interpretation is that ustekinumab now has placebo-controlled trial evidence suggesting short-term benefit in active fistulising perianal Crohn’s disease, while durability, optimisation, comparative positioning, and implementation remain important unanswered questions. Five Key Clinical Takeaways The GETAID trial was a double-blind, multicentre, randomised placebo-controlled trial of ustekinumab in active fistulising perianal Crohn’s disease. Thirty-two patients were randomised across 10 French centres; 69% had prior anti-TNF failure, making the population clinically relevant but specialised. At week 12, combined clinical and radiological remission occurred in 62% with ustekinumab versus 25% with placebo. The primary endpoint combined absence of drainage from all external fistula openings with absence of abscesses larger than 2 cm on blinded central MRI. The study supports a short-term treatment signal for ustekinumab, but small sample size, wide confidence intervals, and open-label crossover limit conclusions about durability and comparative positioning. Source Reference and Link Wils P, Nancey S, Messmer E, et al.; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Ustekinumab for fistulising perianal Crohn’s disease: a randomised placebo-controlled trial from the GETAID. Gut. Published online July 24, 2026. DOI: 10.1136/gutjnl-2026-339158. Trial registration: NCT04496063.

GastroAGI TeamRead more

5 min readJul 29, 202637reads

Maddrey's Discriminant Function: How to Calculate It Correctly

A resident calculates a DF of 28 on a patient with suspected alcoholic hepatitis, rounds the prothrombin time control down for convenience, and misses the steroid-eligible cutoff by four points that shouldn't have been there. The formula has two inputs and one constant - and it's still one of the most commonly miscalculated bedside scores in hepatology. This post walks through exactly how to calculate it, which control PT to use, and where the errors creep in. Maddrey's discriminant function (MDF) is calculated as 4.6 × (patient's prothrombin time in seconds − control prothrombin time in seconds) + total bilirubin in mg/dL . Every input looks straightforward until you're the one entering it: which control PT your lab uses isn't standardized, bilirubin units get mixed up between mg/dL and µmol/L, and a lab-to-lab difference in control PT of even 1–2 seconds can shift the calculated DF enough to change whether a patient crosses the 32-point threshold. Getting the Maddrey discriminant function formula right isn't a triviality before the clinical decision - it's the clinical decision, since the entire score exists to answer one binary question at one specific cutoff. Check out: MELD-Na score interpretation The Formula, Step by Step Start with the two lab values you need: total bilirubin (mg/dL) and prothrombin time (seconds), plus your lab's control PT - the reference PT value your coagulation lab uses for a healthy control, not the patient's own baseline. Subtract the control PT from the patient's measured PT, multiply that difference by 4.6, then add the total bilirubin. So a patient with a PT of 22 seconds, a lab control PT of 12 seconds, and a bilirubin of 9.8 mg/dL calculates as 4.6 × (22 − 12) + 9.8 = 55.8. That patient clears the DF >32 threshold associated with roughly 35–45% one-month mortality without treatment, making them a candidate for corticosteroid consideration pending the usual contraindication screen. If bilirubin is reported in µmol/L rather than mg/dL, divide by 17 first - skipping that conversion is one of the most common calculation errors and produces a wildly inflated score. Case in point A 47-year-old man with heavy alcohol use is admitted with jaundice. His bilirubin returns at 9.8 mg/dL and his PT at 21 seconds. The admitting team uses their hospital lab's stated control PT of 12.5 seconds and calculates a DF of 44.9 - clearly above 32. A senior resident recalculates using 13.5 seconds, the control value used in a different published study she remembers, and gets a DF of 42.7. Both numbers land the patient in the same clinical category, but the discrepancy prompts the team to actually check which control PT their own institution's coagulation lab reports. That check matters more than it seems. A retrospective review of 882 patients found that the specific control PT used in the calculation affected whether patients were flagged for steroid consideration, even though it didn't change 30-day survival outcomes - meaning the choice of control PT can move a patient across the treatment-eligibility line without reflecting a real difference in their disease severity. Confirming your institution's control PT value once, rather than assuming a number from memory or a paper, removes that variability entirely. Where the Score Gets Miscalculated in Practice The most frequent real-world error isn't the arithmetic - it's using the wrong control PT, either an outdated value, a different lab's published constant, or, occasionally, the patient's own PT from a prior admission mistaken for a control value. Always use your own coagulation lab's stated control PT, printed on most PT/INR reports or available from lab services directly, not a number memorized from a textbook or a different hospital's protocol. The second common error is unit mismatch on bilirubin, particularly in settings that report in SI units by default. The third, more subtle error is timing: calculating the DF from labs drawn before adequate resuscitation or before an evolving infection is treated can produce a transiently elevated score that doesn't reflect the patient's true baseline severity a day or two later. None of these errors are in the formula itself - the formula is fixed and simple. They're all in the inputs, which is exactly why the score is so easy to get wrong despite being so easy to compute. A frequently overlooked point Clinicians sometimes recalculate the DF daily expecting it to track clinical trajectory the way MELD does, and get confused when a patient looks worse but their DF barely moves. The DF wasn't designed as a continuous severity tracker - it's a single-timepoint threshold test, calculated once at presentation to answer one question. Trending it daily like a MELD score isn't wrong exactly, but it's asking a static eligibility gate to do the job of a dynamic prognostic score, and the number will disappoint you if that's what you expect from it. Bottom line for clinical practice Formula: 4.6 × (patient PT − control PT in seconds) + total bilirubin in mg/dL. Confirm your institution's actual control PT value before calculating - don't use a remembered or textbook figure. Convert bilirubin from µmol/L to mg/dL (divide by 17) before plugging it into the formula if your lab reports in SI units. A DF above 32 is the threshold associated with significant short-term mortality and the trigger for steroid-candidacy evaluation. Calculate once at presentation on stable, resuscitated labs - the DF is a single-timepoint threshold, not a daily trending score. Once you have the number, the harder question is what to do with it - our post on Maddrey's discriminant function and steroid candidacy covers exactly that decision, including the contraindications that make a DF above 32 reversible. And if a patient's picture involves both alcoholic hepatitis and cirrhosis, MELD-Na score interpretation breaks down which score answers which question. Run the calculation through GastroAGI directly and skip the control-PT guesswork entirely.

GastroAGI TeamRead more

8 min readJul 28, 202625reads

Artificial General Intelligence in Healthcare: What Gastroenterologists and Hepatologists Should Know Now

Could a future AI system integrate symptoms, laboratory data, longitudinal records, imaging, pathology, remote monitoring, and the literature well enough to act as a truly general clinical partner rather than a point tool? That is the unresolved question sitting underneath today’s excitement about artificial general intelligence in healthcare. The source base reviewed here suggests that healthcare is moving in that direction conceptually, but it also shows that most current deployment remains much closer to narrow AI or clinically bounded AI than to human-level general reasoning. For gastroenterologists, hepatologists, fellows, and researchers, the right starting point is therefore not triumphalism. It is disciplined curiosity. Healthcare’s attraction to more capable AI is easy to understand. Several of the supplied sources describe a care environment overwhelmed by data: electronic health records, laboratory results, imaging, sensor streams, pathology, medical literature, and patient-generated information. LTTS points to electronic medical records, PACS, hospital systems, claims data, and surveys as major data streams, while Emorphis emphasizes records, labs, imaging, genomics, wearable data, claims, and clinical notes. HRS similarly frames AI’s appeal around improving decisions, supporting human judgment, and increasing efficiency. For subspecialists who routinely synthesize fragmented information across time, the clinical problem is recognizable even before one reaches the AGI question. A useful clarification comes from Aidoc and Emorphis. Aidoc distinguishes healthcare AI from clinical AI : healthcare AI includes administrative and operational tools, whereas clinical AI is more directly aimed at patient care and clinician decision-making. Emorphis, by contrast, draws the line between today’s narrow AI and a hypothetical AGI that could reason across multiple domains, adapt to new scenarios, and integrate diverse types of information. That distinction matters for clinician expectations. Much of what is already being implemented in hospitals today belongs to the narrower side of that spectrum: image triage, workflow support, notification systems, documentation, or patient routing. The stronger the claim sounds like generalized physician reasoning, the weaker the evidence base becomes in the source set you provided. One of the most clinically intuitive scenarios is multimodal diagnostic synthesis . Emorphis argues that an AGI-capable system could combine imaging, history, genetics, labs, lifestyle, and environmental context rather than interpret each stream in isolation. LTTS similarly describes AI-enabled EHRs that support suggestive diagnosis, disease risk estimation, and progression pathways, and it highlights radiology and pathology as areas where AI may improve speed and accuracy. Translated for a gastroenterology or hepatology reader, the attraction is obvious: many real patients do not present as single-data-type problems. They arrive with symptoms, prior procedures, medication exposure, serial labs, pathology, imaging, and changing risk factors. The source base supports the idea that broader data integration could improve diagnostic support, but it does not establish GI-specific performance, causation, or superiority over specialist care. A second scenario is personalized treatment planning . Emorphis describes AGI as potentially able to evaluate prior treatment responses, monitor real-time change, predict complications, and recommend dynamic adjustments. LTTS puts similar weight on precision medicine, especially where genomics, environment, lifestyle, and history may allow a shift away from one-size-fits-all care. The Medium piece extends the same argument to individualized treatment selection. For clinicians in chronic digestive disease, this is an appealing vision: not because current sources prove it in GI, but because the logic of individualized longitudinal care is already central to subspecialty practice. What the sources support is a conceptual pathway toward more tailored recommendations. What they do not support is any conclusion that AGI has already validated treatment personalization in gastroenterology or hepatology, or that it should alter guideline-based care today. A third scenario concerns care navigation, chronic disease follow-up, and remote monitoring . The BDJ paper describes AI-enabled personalized health information, virtual consultations, and remote monitoring as ways of improving access and allowing earlier intervention. Emorphis argues that wearable and home-device data could help detect deterioration and trigger proactive intervention. Infermedica’s AI-in-healthcare category emphasizes care navigation and digital triage, and HRS frames the broader future of AI around a shift from reactive to preventive care. For GI and liver clinicians, this is one of the more practical areas to watch because it starts from workflow and access, not from claims of autonomous diagnosis. Still, the source set remains largely descriptive. It supports the plausibility of earlier outreach and better routing, but it does not provide GI-specific evidence that such systems reduce decompensation, flare rates, procedure delays, or hospitalizations. A fourth and more immediately tangible area is image and tissue interpretation , although this is arguably where the conversation is more about advanced clinical AI than AGI. Dave and Patel discuss AI in medical radiology and diagnostic histopathology, including image analysis, automated tissue segmentation, predictive analysis, and quality control. LTTS likewise describes AI contributions to medical imaging and pathology review, and Aidoc’s guide emphasizes the distinction between broader healthcare AI and patient-care-focused clinical AI. For clinician readers, this matters because it is closer to the present tense. The source set suggests that imaging and pathology are among the most concrete domains for implementation because the task boundaries are clearer and the inputs are more structured. But that should not be mistaken for proof that “general intelligence” has arrived. The most credible near-term reading is that bounded, validated, workflow-embedded tools are a more realistic bridge than full-spectrum AGI. A fifth scenario is administrative relief and operational redesign . Emorphis lists workforce planning, scheduling, supply chain management, revenue cycle optimization, and workflow automation among likely AGI-related applications. LTTS similarly discusses appointment scheduling, billing, insurance claims, coding, demand forecasting, and regulatory monitoring. The Medium article adds patient flow and staffing optimization to the human-AI partnership theme. HRS, meanwhile, argues that AI is more likely to enhance clinicians than replace them. This cluster of use cases deserves more attention than it often gets in academic discussions because operational friction is itself a clinical issue. When documentation, routing, coding, or follow-up logistics fail, patient care degrades. Even so, operational usefulness should not be conflated with validated clinical outcome benefit. The sources support probable workflow value; they do not prove downstream causal improvements in specialty outcomes. A sixth scenario is research acceleration and drug development . Emorphis and the Medium article describe AGI as a possible catalyst for hypothesis generation, target identification, drug interaction prediction, and simulation of clinical trial outcomes. LTTS adds in silico testing and large-scale analysis of clinical trial and real-world datasets. For researchers in digestive disease and hepatology, this may be one of the most strategically important long-range themes because the literature burden, biomarker complexity, and translational pipeline are already difficult to manage with conventional analytic approaches. Yet here again the evidence posture matters. The sources support a future-oriented claim that AI could accelerate discovery; they do not document a completed AGI-driven transformation in specialty therapeutics, and they do not establish whether faster model-driven discovery reliably translates into safer or better treatments. The source set also raises an underappreciated domain for clinician leaders: education and professional adaptation . Dave and Patel explicitly extend the AI conversation into medical and dental education and even scientific publishing. HRS notes that healthcare workers will need stronger fluency in data and analytics as AI becomes more embedded in care delivery. Infermedica’s 2025 materials add a complementary emphasis on validation and regulated deployment, suggesting that the clinical task is not merely learning to use AI tools, but learning to interrogate them: What was validated, for whom, under what regulatory framework, and with what failure modes? That mindset may be especially important for fellows and early-career clinicians, because the real change may be less about replacing decision-makers and more about changing what competent decision-making requires. So what should clinicians conclude from this evidence base? First, there is consistent cross-source agreement that AI’s opportunities in healthcare cluster around data synthesis, earlier identification of risk, personalization, triage, monitoring, clinical support, workflow redesign, and research acceleration. Second, there is also cross-source agreement that privacy, bias, transparency, safety, patient trust, and regulation are not side issues; they are core adoption constraints. Emorphis names privacy, explainability, bias mitigation, and trust directly. LTTS emphasizes privacy, security, and compliance. Infermedica’s recent validation- and certification-focused materials show that some parts of the field are moving from abstract enthusiasm toward trust-building and quality systems. What clinicians should not conclude is equally important. The current source set does not justify the claim that AGI has been proven to improve GI-specific outcomes. It does not show that AGI should replace specialist judgment, that it is ready to redefine standards of care, or that conceptual scenarios in personalization and multimodal reasoning already constitute established clinical guidance. Most of the material is scenario-driven, strategic, or implementation-oriented. Even the strongest academic source is a narrative perspective, not a comparative effectiveness study. That difference is the line between possibility and proof. For practice and research, the most responsible path is therefore incremental and evidence-seeking. In the near term, GI and hepatology leaders should probably be most interested in clinically bounded tools with transparent workflows, measurable task definitions, and some validation or regulatory maturity. In the medium term, the more ambitious promise is connective intelligence: systems that can unify records, imaging, pathology, monitoring, and literature into actionable support. In the long term, the AGI question remains open. But if that future arrives, it will still have to earn clinical trust the old-fashioned way: by showing where it works, where it fails, and whether it improves decisions, workflows, or patient outcomes in defined settings rather than in abstract prose. Key clinical takeaways The strongest scholarly source in the supplied set is a peer-reviewed perspective paper , not a clinical trial, so the overall evidence base is best read as conceptual and implementation-oriented rather than outcomes-proving . The most realistic near-term benefits for clinicians appear to be bounded clinical AI and workflow tools such as diagnostic support, digital triage, remote monitoring, pathology or imaging support, and documentation or operational automation. The supplied sources consistently frame future value around multimodal data integration, personalization, earlier detection, and proactive care , but they do not establish GI-specific causal benefit or justify changing specialty standards of care. For clinician adoption, validation, explainability, privacy, bias mitigation, regulatory compliance, and trust are not secondary concerns; they are central determinants of whether an AI tool should be used at all. The most defensible practice stance today is to treat AGI as a strategic horizon while evaluating present-day tools task by task, with clear attention to workflow fit, clinical governance, and specialty-specific evidence gaps. Source references Primary peer-reviewed source: Dave M, Patel N. Artificial intelligence in healthcare and education . British Dental Journal. May 2023; 234(10):761–764.

GastroAGI TeamRead more

5 min readJul 28, 2026148reads

Rome V Criteria for IBS: What the New Frequency Threshold Actually Changes

A 29-year-old presents with cramping abdominal discomfort - not quite pain - three days a month, tied loosely to altered stool form. Under Rome IV, she doesn't meet criteria for IBS. Under Rome V, published May 2026, she does. Same patient, same symptoms, different diagnosis. This post walks through exactly what changed and why it matters for how you code, treat, and counsel patients starting now. Rome IV tightened IBS diagnosis considerably from Rome III, requiring abdominal pain - not discomfort - at least one day per week over the preceding three months. That threshold was defensible on paper but never sat well in clinic: patients who plainly had IBS by every other measure kept landing in "unspecified functional bowel disorder" because their symptom diary didn't clear the bar. Rome V is a direct response to that mismatch, part of the broader overhaul of the disorders of gut-brain interaction framework published in May 2026 . The core diagnostic criteria for Rome V IBS now better reflect how patients actually present, and getting the threshold change right matters for coding accuracy, trial eligibility, and - increasingly - for not dismissing patients whose symptoms are real but don't fit last decade's cutoff. What Changed From Rome IV to Rome V Two specific revisions define the update. First, abdominal discomfort is back as a qualifying symptom alongside pain - Rome IV had dropped discomfort entirely, requiring pain specifically. That exclusion turned out to systematically underrepresent patients in populations where discomfort, rather than frank pain, is the dominant descriptor of their symptoms. Second, and more consequential in practice: the frequency requirement dropped from at least one day per week to at least three days per month over the same three-month window. This wasn't an arbitrary loosening. A global epidemiology study spanning more than 50,000 individuals found the stricter Rome IV threshold cut measured IBS prevalence roughly in half - from around 10% down to 4% - not because fewer people had the condition, but because the weekly-pain requirement screened out patients with clinically significant, intermittent symptoms. The rest of the IBS framework - the requirement that symptoms relate to defecation, a change in stool frequency, or a change in stool form, with at least two of three present - carries over from Rome IV largely intact. This is a recalibration of sensitivity, not a rewrite of the underlying construct. Case in point A 34-year-old woman has intermittent lower abdominal cramping that partially resolves after a bowel movement, occurring on roughly three days most months, alongside loose stools on those same days. She has no alarm features - no weight loss, no rectal bleeding, no nocturnal symptoms, no family history of IBD or colorectal cancer, and basic labs are unremarkable. Under Rome IV, her symptom frequency falls short of the once-weekly pain threshold, and she's technically classified as an unspecified functional bowel disorder despite a textbook clinical picture. Reassessed under Rome V, she meets criteria for IBS with predominant diarrhea outright. The diagnosis doesn't change her workup - she still didn't need a colonoscopy based on her age and lack of alarm features either way - but it changes what you tell her, how you code the encounter, and whether she's eligible for IBS-specific trials or FDA-approved IBS therapies that require a formal diagnosis to prescribe. Applying the New Threshold in Practice The practical shift is in how you take the history. Where a Rome IV-era clinician might ask "how often do you get pain, and is it at least weekly," the Rome V-appropriate question is broader: "how often do you notice pain or discomfort, and does three days a month sound right." Patients who previously answered "off and on, maybe a few times a month" and got waved off as non-diagnostic now clear the bar. This matters most for two groups: patients with genuinely intermittent symptoms who were previously under-coded, and patients whose native symptom vocabulary leans toward "discomfort" or "unease" rather than "pain" - a pattern noted more often in some populations than others, which was part of the rationale for reincluding discomfort in the first place. The subtype classification itself - IBS-C, IBS-D, IBS-M, IBS-U, based on predominant stool pattern - is unchanged. What's changed is simply how many patients clear the gate to be classified at all. As with Rome IV, the diagnosis remains clinical: alarm features still warrant investigation regardless of how neatly a patient fits the symptom criteria. A frequently overlooked point The instinct with any loosened diagnostic threshold is to worry about overdiagnosis, but that's not really the risk here - the risk under Rome IV was underdiagnosis, and Rome V is a correction toward accuracy, not a lowering of the bar for convenience. The patients newly captured by the three-day-a-month threshold aren't marginal cases invented by a committee; they're the same patients who were always symptomatic and simply weren't being counted. If anything, clinicians who kept a mental Rome III-era threshold running in the background - treating patients as IBS based on clinical gestalt even when Rome IV technically excluded them - will find Rome V finally matches what they were already doing. Bottom line for clinical practice Recheck your mental frequency threshold: Rome V requires symptoms at least three days per month, not one day per week, over the preceding three months. Abdominal discomfort now qualifies alongside pain - don't discount a patient because they describe unease rather than frank pain. The two-of-three defecation-related criteria (relation to bowel movement, change in stool frequency, change in stool form) are unchanged from Rome IV. IBS subtyping (IBS-C, IBS-D, IBS-M, IBS-U) is unaffected - only the qualifying threshold to reach a diagnosis has moved. Alarm features still override symptom criteria entirely; Rome V doesn't change your threshold for further workup. Running a borderline case through the new thresholds by hand is exactly the kind of check GastroAGI is built for. And once a patient is confirmed under the new criteria, treatment selection is its own decision tree - our post on SNRIs and other neuromodulators in IBS covers that next step. Walk a case through GastroAGI directly and it'll flag whether a patient clears Rome V criteria, no manual recalculation required. Try GastroAGI .

GastroAGI TeamRead more

10 min readJul 25, 202632reads

Fluorescence-Guided Molecular Imaging in GI Oncology: What the AGA Lumicell Spotlight Signals for Future Cancer Resection

For every clinician involved in gastrointestinal cancer care, one question remains central after a tumor is removed: was all clinically meaningful disease actually cleared? Surgeons, therapeutic endoscopists, oncologists, pathologists, radiologists, and gastroenterologists approach this question from different angles. The surgeon sees the operative field. The endoscopist sees mucosal and submucosal planes. The pathologist sees the specimen after removal. The oncologist thinks in terms of recurrence risk and systemic disease. Yet the decision that matters most to patients is often made across time: cancer is removed during the procedure, but certainty about residual microscopic disease may come later. A recent American Gastroenterological Association innovation spotlight, titled “Startup spotlight: Lumicell – illuminating the future of surgical oncology,” published on July 20, 2026 , brings this unresolved problem into focus. The piece highlights Lumicell, a 2026 AGA Shark Tank participant developing fluorescence-guided molecular imaging for real-time cancer detection during surgery. The technology is not currently presented as established GI oncology practice. Rather, the AGA spotlight frames it as an innovation with potential implications for surgical oncology and, possibly in the future, advanced endoscopic interventions. The clinical problem: residual disease is often a delayed diagnosis The AGA spotlight identifies one of the most difficult problems in solid tumor surgery: knowing before the operation ends whether all cancer has truly been removed. Despite advances in imaging and pathology, microscopic residual disease may remain undetected during surgery. In breast-conserving surgery, this uncertainty can lead to second operations after postoperative pathology identifies positive margins. The AGA article notes that similar challenges exist in gastrointestinal oncology, where clinicians must balance oncologically sound resection with preservation of healthy tissue. That balance is especially relevant to GI cancer care. Colorectal, gastric, pancreatic, and esophageal cancer operations often require careful trade-offs between complete tumor clearance and preservation of organ function, anastomotic integrity, quality of life, and procedural morbidity. Even in advanced endoscopy, the same logic applies at a different scale: endoscopic mucosal resection, endoscopic submucosal dissection, and endoscopic full-thickness resection increasingly aim to remove early neoplasia while preserving anatomy. The limitation of current practice is not that clinicians lack skill or imaging altogether. It is that intraoperative and intraprocedural decision-making remains constrained by what can be seen, palpated, sampled, or later confirmed by pathology. The AGA spotlight describes current surgical reliance on visual inspection, palpation, frozen section, and permanent pathology, while noting that these approaches may either lack sensitivity or not be available in real time. What the AGA spotlight investigated This update is best classified as society innovation news , not a clinical trial report, guideline, systematic review, or practice recommendation. The article profiles Lumicell as a 2026 AGA Shark Tank participant and describes the company’s technology, regulatory milestone in breast-conserving surgery, and potential relevance to broader surgical oncology. The technology focus is fluorescence-guided molecular imaging for real-time cancer detection during surgery . The AGA source describes Lumicell as founded in 2008, headquartered in Newton, Massachusetts, and at a commercial stage with an FDA-approved platform for breast cancer resection while GI oncology work is ongoing. That distinction is essential. The population directly connected to FDA approval in the AGA article is breast-conserving surgery, not GI cancer. The GI relevance is forward-looking and translational. The article does not report a completed GI oncology randomized trial, GI-specific diagnostic accuracy estimates, recurrence outcomes, margin-negative resection rates, or survival data. Therefore, any GastroAGI interpretation must treat the GI implications as plausible future directions rather than established clinical benefit. The technology: molecular signal at the surgical cavity Lumicell’s platform, as described by AGA, combines an intravenously administered, protease-activated fluorescent imaging agent, LUMISIGHT™ / pegulicianine , with a handheld imaging device that detects fluorescence within the surgical cavity after the primary tumor has been removed. The purpose is to help surgeons visualize suspicious residual tissue during the same operation rather than waiting days for pathology results. This concept is important because it shifts imaging from anatomy alone toward molecular activity. The AGA article frames the platform as a combination of molecular imaging, optical engineering, and real-time clinical decision support. In practical terms, the promise is not merely a brighter operative field. It is the possibility of identifying tissue that may carry a tumor-associated molecular signal and using that information while there is still an opportunity to resect additional tissue. However, the clinical word “suspicious” matters. Fluorescence is not the same as a final histopathological diagnosis. The AGA spotlight does not state that fluorescence-guided imaging replaces pathology, nor does it provide GI-specific accuracy metrics. For clinicians, the correct interpretation is that molecular imaging could become an adjunct to operative or endoscopic judgment, not a substitute for pathological confirmation. Why GI clinicians should care, even before GI adoption At first glance, a technology approved for breast-conserving surgery may seem distant from everyday gastroenterology. But the AGA spotlight argues that the underlying concept has broader implications for surgical oncology, including gastrointestinal malignancies where complete tumor removal remains fundamental to outcomes. This is where the update becomes relevant for gastroenterologists and GI oncologists. Modern GI cancer care is increasingly multidisciplinary. Gastroenterologists diagnose and stage disease, identify high-risk lesions, perform therapeutic resections for selected early cancers, manage surveillance, and participate in MDT decisions about surgery, oncology, and follow-up. Technologies that improve intraoperative or intraprocedural detection of residual neoplasia could eventually affect these workflows. The AGA article specifically points toward complex colorectal, gastric, pancreatic, and esophageal cancer resections, where complete tumor removal must be balanced against preserving normal tissue. It also notes that molecular imaging may eventually influence advanced endoscopic interventions as EMR, ESD, and full-thickness resection become more sophisticated. That “eventually” should not be ignored. It signals potential, not readiness. But it is a relevant potential because advanced endoscopy is moving toward increasingly precise, organ-preserving oncologic therapy. Better visualization of residual neoplasia could theoretically support more complete resection, better margin assessment, or more informed decisions about additional therapy. The current AGA source does not prove those outcomes in GI practice. The AGA innovation ecosystem around this update The Lumicell spotlight sits within a broader AGA strategy to connect clinicians, researchers, entrepreneurs, and industry around GI innovation. AGA’s New Technology & Techniques page states that the organization is committed to driving innovation so future gastroenterologists have new tools to care for digestive disease patients. It also lists the AGA Incubator Showcase at DDW 2026 and describes AGA’s partnership with MATTER, through which members can access resources for building health care solutions. AGA also describes a GI Opportunity Fund , launched with Varia Ventures, dedicated to investing in fast-growing early-stage companies in the GI space. The same AGA innovation page lists examples of supported companies working across AI-fueled endoscopic procedure recording and trial recruitment, attachable EUS platforms, unsedated transnasal endoscopy, virtual digestive care, and other digestive disease technologies. This matters because innovation in GI is no longer limited to devices used during procedures. It now includes AI-enabled documentation and recruitment, minimally invasive diagnostics, care delivery platforms, molecular imaging, procedure-based therapeutics, and reimbursement-aware implementation strategies. AGA’s presidential innovation coverage from DDW 2026 similarly described innovation as spanning technology, care delivery, workforce development, genomics, proteomics, AI, and policy advocacy. For clinicians, this broader ecosystem matters because the success of a technology rarely depends on performance alone. Adoption also requires training, workflow fit, reimbursement, regulatory clarity, safety monitoring, equitable access, and evidence that the tool improves clinically meaningful outcomes. What clinicians can reasonably infer From the AGA spotlight, clinicians can conclude that fluorescence-guided molecular imaging is being actively developed as a real-time cancer detection strategy and that Lumicell’s platform has achieved FDA approval for breast-conserving surgery. The AGA article states that Lumicell received simultaneous FDA approval in April 2024 for both its imaging agent and imaging system, supported by a multicenter clinical development program in breast-conserving surgery. Clinicians can also conclude that AGA considers this type of platform relevant to the GI innovation community because of its potential implications for surgical oncology and possibly advanced endoscopic interventions. The update explicitly links the concept to colorectal, gastric, pancreatic, and esophageal cancer resections and to the broader evolution of EMR, ESD, and full-thickness resection. But clinicians should not infer GI clinical efficacy from this spotlight. The AGA source does not present GI-specific trial results. It does not establish that fluorescence-guided molecular imaging reduces repeat surgery in GI cancers, improves R0 resection rates, reduces recurrence, improves survival, or changes endoscopic management. Those would require GI-specific prospective evidence. What this does not mean for current practice This update should not be interpreted as a recommendation to incorporate Lumicell’s platform into routine GI oncology or advanced endoscopy practice today. The AGA source describes GI oncology work as ongoing, while the current FDA-approved platform referenced is for breast cancer resection. It also should not be interpreted as evidence that molecular imaging can replace frozen section, permanent pathology, endoscopic assessment, cross-sectional imaging, or multidisciplinary review. The technology is described as providing real-time decision support, not definitive histology. For gastroenterologists, the appropriate stance is informed caution. The field should watch fluorescence-guided molecular imaging closely, particularly as organ-preserving approaches expand. But it should demand the same evidence standards expected of other cancer technologies: clearly defined indications, diagnostic accuracy, effect on management decisions, patient-centered outcomes, procedural safety, cost-effectiveness, and reproducibility across centers. Evidence gaps that matter before GI implementation Several evidence gaps remain. First, GI-specific diagnostic performance is not established in the AGA spotlight. Future studies would need to define sensitivity, specificity, positive predictive value, and negative predictive value for residual cancer detection in specific GI tumors and procedural contexts. Second, clinical utility must be demonstrated. A test can detect a signal without improving outcomes. The clinically relevant question is whether fluorescence-guided imaging changes intraoperative or endoscopic decisions in ways that improve margin status, reduce repeat procedures, avoid unnecessary tissue removal, or improve oncologic outcomes. Third, anatomical and biological differences across GI cancers matter. Colorectal, gastric, pancreatic, and esophageal tumors differ in operative field, stromal environment, depth of invasion, lymphatic spread, neoadjuvant therapy exposure, and margin assessment. A platform useful in one setting may not translate uniformly across all GI malignancies. Fourth, implementation must be practical. Intravenous imaging agents, handheld devices, operative timing, fluorescence interpretation, regulatory indications, training, and cost all influence whether a technology can move from innovation showcase to routine care. Finally, the role in advanced endoscopy requires separate evaluation. EMR, ESD, and full-thickness resection operate in different visual and technical environments than open or minimally invasive surgery. The source notes potential future relevance to advanced endoscopic interventions, but does not provide evidence of endoscopic performance. Why this is still worth GastroAGI attention The reason to cover this update is not that it changes clinical practice today. It is worth covering because it illustrates the direction of GI oncology innovation: moving from delayed pathology-dependent feedback toward real-time, biologically informed procedural decision support. This direction aligns with several visible trends in gastroenterology. AGA’s innovation materials highlight AI-fueled endoscopic recording and patient recruitment tools, attachable EUS platforms, unsedated transnasal upper endoscopy, and virtual digestive care models. AGA’s DDW innovation coverage also emphasized AI, genomics, proteomics, workforce development, and systems-level readiness for future GI care. Lumicell fits into this broader narrative as a molecular imaging example. It is neither purely software nor a conventional device. It represents a drug-device imaging platform designed to make cancer biology visible during a procedure. For clinicians and researchers, that is an important conceptual shift. Clinical Takeaway AGA’s “Startup spotlight: Lumicell – illuminating the future of surgical oncology” is a society innovation update, not a GI clinical trial or guideline. It highlights a fluorescence-guided molecular imaging platform that is FDA-approved for breast-conserving surgery and being explored for broader oncology applications, with GI oncology work ongoing. For gastroenterologists, hepatologists, fellows, and GI oncology researchers, the key message is cautious interest. Real-time molecular imaging could eventually support more precise cancer resection and possibly advanced endoscopic therapy, but the current source does not establish GI-specific clinical benefit. The update is useful for awareness, innovation tracking, and research horizon scanning—not for changing current GI cancer management. Five key clinical takeaways Evidence label: Society innovation news / technology spotlight, not a guideline, randomized trial, or GI outcome study. Article verified: AGA published “Startup spotlight: Lumicell – illuminating the future of surgical oncology” on July 20, 2026 . Technology described: Lumicell’s platform uses an intravenously administered protease-activated fluorescent imaging agent with a handheld imaging device to detect fluorescence in the surgical cavity after tumor removal. Current approval context: The AGA source states that the platform is FDA-approved for breast cancer resection, while GI oncology work is ongoing. Clinical interpretation: The GI relevance is promising but unproven; clinicians should not infer improved GI cancer margins, recurrence, survival, or endoscopic outcomes without GI-specific prospective evidence. Source reference and link American Gastroenterological Association. “Startup spotlight: Lumicell – illuminating the future of surgical oncology.” Published July 20, 2026. Source: AGA News.

GastroAGI TeamRead more

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

Gastroenterology Insights — Clinical Updates, Guides & Resources — Page 5

IBD Biologic Sequencing After Anti-TNF and Vedolizumab Failure: Choosing the Third-Line Agent

REFINED-ASUC Criteria: A Modern Approach to Diagnosing Acute Severe Ulcerative Colitis

Smoking Cessation in Crohn's Disease: Why E-Cigarettes Belong in the Conversation

Positive FIT Follow-Up: Why Completing Colonoscopy May Matter More Than Timing Alone

2026 ESGE–ESGENA Sedation Guideline for GI Endoscopy: Practical Lessons for Safer Clinical Practice

Ustekinumab for Fistulising Perianal Crohn’s Disease: What the GETAID Trial Adds to Clinical Practice

Maddrey's Discriminant Function: How to Calculate It Correctly

Artificial General Intelligence in Healthcare: What Gastroenterologists and Hepatologists Should Know Now

Rome V Criteria for IBS: What the New Frequency Threshold Actually Changes

Fluorescence-Guided Molecular Imaging in GI Oncology: What the AGA Lumicell Spotlight Signals for Future Cancer Resection

For You

Core Tools

Explore

Gastroenterology Insights — Clinical Updates, Guides & Resources — Page 5

IBD Biologic Sequencing After Anti-TNF and Vedolizumab Failure: Choosing the Third-Line Agent

REFINED-ASUC Criteria: A Modern Approach to Diagnosing Acute Severe Ulcerative Colitis

Smoking Cessation in Crohn's Disease: Why E-Cigarettes Belong in the Conversation

Positive FIT Follow-Up: Why Completing Colonoscopy May Matter More Than Timing Alone

2026 ESGE–ESGENA Sedation Guideline for GI Endoscopy: Practical Lessons for Safer Clinical Practice

Ustekinumab for Fistulising Perianal Crohn’s Disease: What the GETAID Trial Adds to Clinical Practice

Maddrey's Discriminant Function: How to Calculate It Correctly

Artificial General Intelligence in Healthcare: What Gastroenterologists and Hepatologists Should Know Now

Rome V Criteria for IBS: What the New Frequency Threshold Actually Changes

Fluorescence-Guided Molecular Imaging in GI Oncology: What the AGA Lumicell Spotlight Signals for Future Cancer Resection

For You

Core Tools

Explore